<allTrials totalCount="45" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-06-27T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-06-27T00:00:00.000Z">38768940</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of socioeconomic impact of rheumatological care to patients with temporary work disability of musculoskeletal origin</title>
      <scientificTitle/>
      <acronym>IT-ME-98</acronym>
      <studyHypothesis>A population-based, clinical program offered to patients with recent-onset work disability caused by Musculoskeletal Disorders (MSDs) is cost-effective with respect to standard care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy was defined as the differences between groups in the following:
1. Duration of all episodes of MSD-related temporary work disability
2. Number of episodes of MSD-related temporary work disability per patient, assessed one year after the end of inclusion period
3. Number and outcome of proposals for permanent work disability</primaryOutcome>
      <secondaryOutcome>1. Relative efficacy is expressed as the percentage of days on temporary work disability saved per patient and as the total number of days on temporary work disability saved in the intervention group (number of episodes in the intervention group x [mean duration of episodes in control group - mean duration of episodes in intervention group]). 
2. Cost-efficacy was defined as the amount of money required to save 1 day of temporary work disability. 
3. Cost-benefit was defined as dollars invested divided by dollars saved. 
Net benefit was defined as dollars saved minus dollars invested.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the institutional review board of the Hospital Clínico San Carlos and reviewed by the Fondo de Investigaciones Sanitarias (the research agency of the Ministry of Health). Date of approval June 2, 1998.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38768940</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FIS 98/1050</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, controlled study, unblinded for both patients and physicians, of two years duration (recruitment one year, follow-up one year)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6cdc254f-7579-4710-9ebc-ba993abb56f3">
	  <name>Servicio de Reumatología</name>
	  <address/>
	  <city>Madrid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>28040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The issue of a &#147;common diseases&#148; temporary work disability initiation form, with an MSD-related cause reported by the primary care physician. The MSD-related causes included the following: 
1. All arthropathies
2. Connective tissue disorders
3.  Back disorders
4. Soft-tissue rheumatisms
5. Bone and cartilage disorders
6. Musculoskeletal pain not caused by cancer
7. Nerve entrapment syndromes</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>13077</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>13077 (7805 in control group and 5272 in intervention group)</totalTarget>
      <exclusion>1. Patients who had &#147;common diseases&#148; temporary work disability form with an MSD-related cause resulting from trauma or surgery.
2. Patients who had &#147;work accidents&#148; or &#147;professional diseases&#148; noted on the temporary work disability initiation form. Work accidents are primarily sudden, external, violent causes of disease occurring at work or during travel to work, and they represent less than 27% of cases of temporary work disability. Professional diseases include silicosis, asbestos-related mesotelioma, and noise-induced hearing loss, and they represent less than 1% of cases of temporary work disability.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Musculoskeletal disorders causing temporary work disability.</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention was a specific clinical program. The control group received standard care. 

At the first 45-minute visit, patients received a specific diagnosis, reassurance that no serious disease was present, instructions on self-management, instructions on taking medications on a fixed schedule, and information on indications for return to work before complete symptom remission. Return to work was negotiated with patients and was never forced on them. Instructions on self-management included instructions to avoid bed rest, instructions to promote early mobilization of the painful regions, restrictions on the use of splint and neck collars, training in stretching and strengthening exercises, teaching of ergonomic care, delivery of booklets in instances of back or neck pain, and information on optimal levels of physical activity. Patients with higher degrees of disability or abnormal pain behavior received immediate extra reassurance, information on pain-relieving positions, and a telephone call or second visit within 72 hours.

Specific protocols were created for low-back, neck, shoulder, arm and hand, knee, and foot pain and included the three-level clinical-management system described below. Moving a patient from the lower to the upper levels of the system implied the need for further diagnostic or therapeutic procedures and was indicated 1) after a patient spent a predefined period at the lower level without return to work or substantial clinical improvement or 2) by the clinical judgment of the rheumatologist.

At the first level of the system, patients received the clinical management started at the first visit, including a diagnosis based on clinical criteria, pharmacologic treatment of pain and inflammation, pharmacologic treatment of anxiety and depression, peripheral intra- and periarticular injections, and education. Time spent at the first level averaged 2 to 6 weeks. At the second level, patients received maintenance of therapy plus referral for formal rehabilitation and laboratory tests, radiography, computerized tomography, magnetic resonance imaging, and electromyography. After 4 to 8 weeks with no improvement at the second level, patients were moved to the third level and received further diagnostic procedures or referral for surgical or other specialized care. &#147;Red flags&#148; were defined, including age greater than 50 years for patients with axial pain, previous trauma, cancer, serious medical illness, inflammatory pain, night pain, drug abuse, corticosteroid use, fever, weight loss, progressively deteriorating function, and progressive neurologic deficit. The presence of a red flag precluded the use of the level system, and the patient in question was managed according to clinical criteria, with a focus on excluding serious illness.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16172439 Results:
2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17330282 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="44f88743-0171-4518-b33e-e0939e870f9f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16172439"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="8062030f-8dd8-4000-82c6-87302fe6a715" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-03-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17330282"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16590-0</funderId>
      <contactId>Contact54548_16590</contactId>
      <sponsorId>Sponsor53103</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54548_16590">
    <title>Dr</title>
    <forename>Juan Angel</forename>
    <surname>Jover</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Servicio de Reumatología
Hospital Clínico San Carlos
C/ Martín Lagos, s/n</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 330 36 15</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jjover.hcsc@salud.madrid.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53103">
    <organisation>The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain)</organisation>
    <website>http://www.isciii.es/htdocs/en/investigacion/investigacion_presentacion.jsp</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>C/ Sinesio Delgado
Nº 6 (Pabellón Nº 4)</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28029 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 822 21 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Oficina.informacion@isciii.es</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413448.e</gridId>
    <rorId>https://ror.org/00ca2c886</rorId>
  </sponsor>
  <funder id="Funder16590-0">
    <name>Research Funding Agency of the Spanish Ministry of Health (Fondo de Investigación Sanitaria; FIS)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-06-13T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-04-13T00:00:00.000Z">07549334</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to investigate the Effect of Surgery and Compression on Healing And Recurrence in chronic venous ulceration</title>
      <scientificTitle/>
      <acronym>ESCHAR</acronym>
      <studyHypothesis>The surgical correction of superficial venous surgery in addition to compression reduces venous ulcer recurrence in comparison to compression therapy alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Ulcer healing
2. Ulcer recurrence</primaryOutcome>
      <secondaryOutcome>Ulcer free time</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from Gloucestershire Local Research Ethics Committee on the 29th January 1998 (ref: 98/44E).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07549334</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>00PRT/6</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c5042af4-7680-43ae-8b79-09c706c6ce93">
	  <name>Department of Vascular Surgery</name>
	  <address/>
	  <city>Cheltenham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>GL53 7AN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Open or recently healed leg ulceration (within six months) of greater than four weeks duration between knee and malleoli, with Ankle Brachial Pressure Index (ABPI) above 0.85 and duplex evidence of superficial with or without deep venous reflux.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500</totalTarget>
      <exclusion>1. Duplex imaging not possible
2. Patient unable/unwilling to give informed consent
3. Deep venous occlusion
4. Unfit for surgery (even under local anaesthetic)
5. Multilayer compression therapy not practical
6. Malignant ulceration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic venous ulceration</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Venous ulceration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two groups were randomised to either compression therapy alone or compression plus superficial venous surgery.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=15183623 Results ()
2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17545185 Long term results ()</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5b5302bb-11a6-4137-a1ba-2302a4b850b2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-06-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=15183623"/>
	<description>Results ()</description>
	<productionNotes/>
      </output>
      <output id="ab8d912b-061f-4c5c-b69b-0819dc24558d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17545185"/>
	<description>Long term results ()</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16258-0</funderId>
      <funderId>Funder16258-1</funderId>
      <contactId>Contact54213_16258</contactId>
      <sponsorId>Sponsor52767</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54213_16258">
    <title>Mr</title>
    <forename>Keith</forename>
    <surname>Poskitt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Vascular Surgery
Cheltenham General Hospital
Sandford Road</address>
      <city>Cheltenham</city>
      <country>United Kingdom</country>
      <zip>GL53 7AN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52767">
    <organisation>South West NHS R&amp;D Directorate (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Whiteladies Road</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS8 2PR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16258-0">
    <name>Medical Research Council (UK) - interim grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder16258-1">
    <name>South West NHS R&amp;D Directorate (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-03-16T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-14T00:00:00.000Z">98891022</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of admission to psychiatric hospital.  A randomised controlled trial of service use, health and social care outcomes of a community mental health team intervention specific to dual diagnosis (psychosis and substance misuse) patients</title>
      <scientificTitle/>
      <acronym>COMO (Mental health care for dual diagnosis COMOrbidity)</acronym>
      <studyHypothesis>Outcomes were investigated at both staff and patient levels. At the patient level, the primary hypotheses were that, compared with patients on control group care coordinators&#146; caseloads, patients on caseloads of the experimental group key workers, would have: 
1. diminished use of in-patient services, reflected in significantly lower bed day use over an 18-month follow-up period
2. reduced alcohol and drug consumption, reflected in lower quantity of alcohol and drugs consumed over the month before interview

Secondary hypotheses were that the intervention would also be associated with significantly:
1. diminished levels of homelessness, violence, suicidal behaviour, imprisonment and detention under the Mental Health Act
2. better social functioning, particularly in relation to self care and hostile and aggressive behaviour 
3. diminished symptom severity
4. increased adherence to treatment 
5. greater satisfaction with services
6. lower overall costs of care 

Regarding staff, the main hypotheses were that a significant increase: 
1. in  knowledge about dual diagnosis
2. in substance abuse intervention skills and more positive attitudes to working with this client group would be observed in staff receiving the experimental training and supervision package</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Service users: Hospital bed use over the preceding 18 months, including admission to hospitals outside the catchment area on an extra-contractual referral basis. 
Other service use recorded using the Client Service Receipt Inventory 
Case managers: Alcohol and Alcohol Problems Perceptions Questionnaire</primaryOutcome>
      <secondaryOutcome>Service users: 
1. Current adherence to medication, rated using the Medication Compliance Scale, which yields a single rating for the extent to which the patient is believed to adhere to prescribed medication
2. Stage of treatment rated using the Substance Abuse Treatment Scale (SATS), which yields a single rating of the extent to which a patient with dual diagnosis is motivated for and engaged in substance misuse treatment
3. Met and unmet needs, rated using the Camberwell Assessment of Need Short Assessment Schedule (CANSAS), which elicits ratings of patients&#146; needs in 22 social and clinical domains
4. Social functioning, rated using the Life Skills Profile (LSP)
5. Drug and alcohol consumption and associated problems, measured using the section of the Maudsley Addictions Profile (MAP) which records consumption over a month, the Alcohol Use Disorders Identification Test (AUDIT), which screens for alcohol-related problems and may be used to categorise drinking as hazardous or harmful, and the DALI, a screening instrument for problematic drug and alcohol use developed specifically for severely mentally ill populations
6. Service satisfaction, measured by the brief global Client Satisfaction Questionnaire (CSQ-8) and the Treatment Perception Questionnaire, a short instrument developed specifically to assess satisfaction with substance misuse treatment
7. Physical symptoms, rated using the section of the MAP which enquires how often 10 common physical symptoms have been experienced in the past 30 days
8. Psychiatric symptoms, rated using the Brief Psychiatric Rating Scale (extended version)</secondaryOutcome>
      <trialWebsite>http://www.iop.kcl.ac.uk/departments/?locator=342&amp;project=10075</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institute of Psychiatry, Kings College London, Research Ethics Committee, approved in 1999, Ref: 075/99</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98891022</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>GTCUL</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="60003e88-f858-4e40-bce3-5d64836f6050">
	  <name>Health Services and Population Research (PO29)</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE5 8AF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All case managers were invited to participate unless they were temporary staff or had firm plans to leave during the next 18 months. 
Service user inclusion: a clinical diagnosis (made by psychiatrists and recorded in casenotes) of schizophrenia or schizoaffective disorder (ICD 10 codes F20, F25), delusional disorder and other non-affective psychotic illnesses (F22, F29) or bipolar affective disorder (F31) on the caseloads of participating case managers and in addition a rating of  substance "abuse" or  "dependence" on the Clinician Alcohol Use Scale (CAUS) and the Clinician Drug Use Scale (CDUS) based on DSMIII-R criteria.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44 case managers and 220 service users</totalTarget>
      <exclusion>Case managers excluded if they had immediate plans to leave or be absent for the study period service users were excluded if they had diagnoses other than stated above.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe and enduring mental illness and comorbid substance abuse or dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>mental illness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each cluster consisted of the clients on a particular case managers' caseload. The unit of randomisation was the case manager.  The experimental group consisted of case managers (and the service users with dual diagnosis on their case load) who had been randomly allocated to receive training in dual diagnosis interventions and the control group were case managers (and the service users with dual diagnosis on their case load) who had not been allocated to receive training.

Case managers in the experimental group received a 5 day training course in detection, assessment and interventions for people with dual diagnosis that aims to increase engagement with care and increase motivation to reduce or abstain from using drugs and alcohol.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12663845 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1f9a65b5-b111-4b01-8bb5-47caf0a7a994" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12663845"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16132-0</funderId>
      <contactId>Contact54078_16132</contactId>
      <sponsorId>Sponsor52633</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54078_16132">
    <title>Prof</title>
    <forename>Graham</forename>
    <surname>Thornicroft</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Services and Population Research (PO29)
Institute of Psychiatry, Kings College, London
De Crespigny Park
Denmark Hill</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207 848 0735</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.thornicroft@iop.kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52633">
    <organisation>Kings College London (UK)</organisation>
    <website>http://www.kcl.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>The Strand</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>WC2R 2LS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207 836 5454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ceu@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.13097.3c</gridId>
    <rorId>https://ror.org/0220mzb33</rorId>
  </sponsor>
  <funder id="Funder16132-0">
    <name>Culyer grant. Ref: GTCUL (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-27T00:00:00.000Z">30488563</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Wall thickness measurement by ultrasonography as a predictor for arteriovenous fistula function in haemodialysis patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Research to investigate whether ultrasonographically and histologically measured radial artery wall thickness are comparable, and whether this wall thickness is predictive for maturation of arteriovenous fistulas in haemodialysis patients.

Hypothesis:
Radial artery wall thickness is predictive for arteriovenous fistula maturation and can be measured by means of ultrasonography.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Similarity between ulrasonographically measured and histologically measured radial artery wall thickness
2. Patency rates</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30488563</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, non-controlled, parallel group, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3d937948-72e9-4117-9621-74ffee9b0160">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic renal failure and requirement of an arteriovenous fistula
2. Age 18 years or older
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Age less than 18 years
2. Placement of vascular access prosthesis
3. Unable to sign written informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic renal insufficiency</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal insufficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Excision biopsy of a small piece of the radial artery during operation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16245-0</funderId>
      <contactId>Contact54200_16245</contactId>
      <sponsorId>Sponsor52754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54200_16245">
    <title>Dr</title>
    <forename>H J T A M</forename>
    <surname>Huijbregts</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
HP F 03.223
P.O. Box 85500
Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 7379</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">R.Huijbregts@azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52754">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16245-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-27T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-02-27T00:00:00.000Z">12672997</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of treatment with an oral bisphosphonate on markers of bone formation and bone resorption in adults with alkpatonuria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>With this explorative trial we will investigate the effect of treatment with a bisphosphonate on markers of bone formation and bone resorption in patients with this rare metabolic disorder.

Hypothesis:
Treatment with a bisphosphonate leads to a decrease in the level of the marker of bone resorption in a period of three months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Change in bone markers
2. Bone formation: plasma alkaline phosphatase
3. Bone resorption: urine type I collagen cross-linked N-telopeptide</primaryOutcome>
      <secondaryOutcome>Pain using the Visual Analogue Scale (VAS)-score</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12672997</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Explorative trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1bdfae16-0a1f-4581-9bc7-7774edee602a">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with alkaptonuria
2. Osteopenia or osteoporose on Dual Energy X-ray Absorptiometry (DEXA)-scan
3. Age minimally 16 years</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>6</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>6</totalTarget>
      <exclusion>1. Short life expectancy
2. Hepatic or renal disease
3. Excessive use of alcohol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Alkaptonuria</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three months oral treatment with risendronate 5 mg per day</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Risendronate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16247-0</funderId>
      <contactId>Contact54202_16247</contactId>
      <sponsorId>Sponsor52756</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54202_16247">
    <title>Dr</title>
    <forename>H W</forename>
    <surname>de Valk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU) 
Department of Internal Medicine
P.O. Box 85500 
Heidelberglaan 100 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 8323</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.W.devalk@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52756">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands) </organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Internal Medicine 
P.O. Box 85500 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16247-0">
    <name>University Medical Centre Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-27T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-02-27T00:00:00.000Z">49579665</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacokinetics of 6-thioguanine</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Oral 6-thioguanine (6TG) results in a high intra-hepatic exposure to 6TG generated metabolites.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Determination of first pass effect of 6TG metabolites.</primaryOutcome>
      <secondaryOutcome>Determination of influence of different enzymes on 6TG metabolism.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49579665</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, non-controlled, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="35f72265-b442-4ec5-8cd5-9a9a2fdc3662">
	  <name>VU University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Irritable Bowel Disease (IBD)
2. In need of immunosuppressants
3. Intolerant to azathioprine or methotrexate</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Concomitant use of drugs interfering with thiopurine metabolism
2. Pregnancy/lactation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Irritable Bowel Syndrome (IBS), Ulcerative colitis, Crohn's Disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Noninfective enteritis and colitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will receive both 6TG orally and intravenously. On set times (for eight hours) blood will be drawn to determine the concentrations of different metabolites and enzymes.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>6-thioguanine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16251-0</funderId>
      <contactId>Contact54206_16251</contactId>
      <sponsorId>Sponsor52760</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54206_16251">
    <title>Dr</title>
    <forename>K H N</forename>
    <surname>de Boer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Centre
Department of Gastroenterology and Hepatology
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">KHN.deBoer@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52760">
    <organisation>VU University Medical Centre (VUMC) (The Netherlands) </organisation>
    <website>http://www.vumc.nl/english/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16251-0">
    <name>VU University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-26T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">75642432</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is a simultaneous intervention of triamcinolon injections with standardised exercises more effective compared to the usual care according to the Dutch College of Family Physicians standard in patients with shoulder complaints? A prospective, single blind, randomised clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the present study is whether a simultaneus intervention with (maximal five) corticosteroid/lidocaine injections and exercises for the cuff muscles (both according a standard protocol), have better results than a sequential intervention of first (maximal five) corticosteroid/lidocaine injections followed after six weeks by exercises (usual care, according to Dutch College of Family Physicians [NHG] standard) in a group of patients with shoulder complaints.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is the change in pain in rest, during activities or during the night of the last 24 hours, between baseline and 78 weeks.</primaryOutcome>
      <secondaryOutcome>Change compared to the baseline assessments of:
1. Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire
2. Short Form health survey (SF-36) questionnaire
3. Analgesic use
4. Participant rated improvement
5. Range of motion maesurements
6. Painful-arc
7. Complications of injections</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75642432</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="417c2c11-b63e-4523-8a78-03ecd164a313">
	  <name>Vrieseweg 157</name>
	  <address/>
	  <city>Dordrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3311 NV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with shoulder complaints consulting their General Practitioner (GP)
2. Presence of painful-arc and restricted range of motion</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>205</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>205</totalTarget>
      <exclusion>1. Not signed informed consent form
2. Age under 18 or above 70 years
3. Treatment (exercises or corticosteroid injections) of shoulder complaints during the last six months
4. Insufficient command of the Dutch language, spoken and/or written</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Triamcinolon injections, Dutch College of Family Physician (NHG) standard, complaints of shoulder, exercises, efficacy</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Shoulder complaints</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A: the patients will be injected with a combination of lidocaine and 1 ml kenacort A40 and at the same time exercises
Group B: the patient will be injected with a combination of lidocaine and 1 ml Kenacort A40 and after six weeks according to the NHG-standard with exercises</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lidocaine, kenacort</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16223-0</funderId>
      <contactId>Contact54178_16223</contactId>
      <sponsorId>Sponsor52732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54178_16223">
    <title>Dr</title>
    <forename>B J</forename>
    <surname>Berkhout</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrieseweg 157</address>
      <city>Dordrecht</city>
      <country>Netherlands</country>
      <zip>3311 NV </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)78 614 4000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">berkh994@planet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52732">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Orthopaedics
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 5088</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.meuffels@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16223-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-09T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-02-21T00:00:00.000Z">07698599</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development and evaluation of a pedagogical tool to improve the understanding of a quality checklist: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>CILS</acronym>
      <studyHypothesis>Assessing the quality of reports of Randomised Controlled Trials (RCTs) is particularly important for clinicians&#146; critical appraisal of the healthcare literature and for systematic reviewers. In fact, evidence suggests that inadequate reporting is associated with biased treatment effect estimates. Quality assessment is often achieved by use of checklists or scales. In the field of Non Pharmacological Treatment (NPT), a checklist - the checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) - was developed to assess the quality of RCTs included in meta-analysis. However, reproducibility issues have been raised because these checklists use items inconsistently defined and not well understood by reviewers such as blinding, dropout and withdrawals or an intention-to-treat analysis. To improve the understanding of the CLEAR NPT, we developed an Internet-based Computer Learning System (ICLS). To evaluate the impact of the ICLS on proper coding with the CLEAR NPT, we carried out an RCT comparing ICLS to no specific training.

The aim of this study was to develop and evaluate a pedagogical tool to enhance the understanding of a checklist that evaluates reports of Non Pharmacological Trials (CLEAR NPT).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was the rate of correct answers compared to a criterion standard for coding a report of randomised controlled trials with the CLEAR NPT.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes were the rate of correct answers for each item and a qualitative assessment of the ICLS by the survey participants completed after fulfilling the training program.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>No ethical approval required as no patients were tested for this trial.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07698599</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial comparing two groups of participants</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dcc990e7-9919-4d83-9c68-2a851a95ee6d">
	  <name>Département d'Epidémiologie Biostatistique et Recherche Clinique</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75018</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Members from three different categories of participants were invited by e-mail to participate in the randomised controlled trial:
1. Members of Health Technology Assessment international (HTAi) (n = 430)
2. Directors of Evidence-based Practice Centers (EPC) (n = 13) who develop systematic reviews and technology assessments on topics relevant to clinical, social science/behavioural, economic, and other healthcare organisation and delivery issues
3. Corresponding authors of meta-analyses of NPT published between 1st January 2004, and 3rd March 2006 (n = 100)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>78</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>78</totalTarget>
      <exclusion>Participants not completing inclusion criterias</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Improving the understanding of a quality checklist</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Training health professionals</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>We developed an Internet-based Computer Learning System (ICLS). This pedagogical tool used many examples from published randomised controlled trials to demonstrate the main coding difficulties encountered when using this checklist. 

Randomised participants received either a specific web-based training with the ICLS (intervention group) or no specific training.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17479163 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="46423d71-2221-4e32-9d15-7187e9f4f19d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17479163"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15930-0</funderId>
      <contactId>Contact53874_15930</contactId>
      <sponsorId>Sponsor52425</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53874_15930">
    <title>Dr</title>
    <forename>Isabelle</forename>
    <surname>Boutron</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Département d'Epidémiologie Biostatistique et Recherche Clinique
INSERM U738
Groupe Hospitalier Bichat-Claude Bernard
46 rue Henri Huchard</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75018</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">isabelle.boutron@bch.ap-hop-paris.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52425">
    <organisation>National Academy of Medicine (Académie Nationale de Médecine) (France)</organisation>
    <website>http://www.academie-medecine.fr/index.cfm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>16 rue Bonaparte  </address>
      <city>Paris</city>
      <country>France</country>
      <zip>75272</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.461915.e</gridId>
    <rorId>https://ror.org/01b266018</rorId>
  </sponsor>
  <funder id="Funder15930-0">
    <name>This work was supported by a grant from the National Academy of Medicine (Académie Nationale de Médecine) (France).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-14T00:00:00.000Z">07173607</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Do positive end-expiratory pressure-induced changes in cardiac output indicate fluid responsiveness in anaesthetised patients?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The magnitude of changes in cardiac output induced by alternating Positive End-Expiratory Pressures (PEEP) predict fluid responsiveness in anaesthetised patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Coherence between the magnitude of the PEEP-induced alterations of SV and the patients fluid responsiveness.</primaryOutcome>
      <secondaryOutcome>1. Coherence between the magnitude of PEEP-induced alterations of pulse pressure and the patients fluid responsiveness
2. Coherence between the magnitude of PEEP-induced alterations of heart rate and the patients fluid responsiveness</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by The Scientific Ethical Committee of North Denmark Region on 13th December 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07173607</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, single centre, non-randomised or blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Other</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8bff5bb5-350a-4681-a9d2-6c6a2289847e">
	  <name>Anaesthesia and Intensive Care Medicine of North Denmark Region</name>
	  <address/>
	  <city>Aalborg</city>
	  <state/>
	  <country>Denmark</country>
	  <zip>9000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients admitted to Aalborg Hospital for elective surgery of the spinal column.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Severe right-sided cardiac insufficiency
2. Severe anaemia
3. Pregnancy
4. Children (age less than 18 years)
5. Patients without esophageal doppler monitoring of cardiac output
6. Patients who experience severe complications during anaesthesia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Anaesthetised patients</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>While monitoring cardiac Stroke Volume (SV) we alternate the Positive End-Expiratory Pressure (PEEP) by 10 cm H2O. If the PEEP-alteration results in a change in SV of more than 5 mL we hypothesise that the patient is fluid responsive. 

Subsequently  we measure SV before and after loading the patient with 250 mL of Hydroxyethyl Starch (Voluven®) to obtain a measure of the patients fluid responsiveness.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydroxyethyl Starch (Voluven®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16013-0</funderId>
      <contactId>Contact53959_16013</contactId>
      <sponsorId>Sponsor52508</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53959_16013">
    <title>Prof</title>
    <forename>Anders</forename>
    <surname>Larsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Anaesthesia and Intensive Care Medicine of North Denmark Region
Aalborg Hospital
Hobrovej 18-22</address>
      <city>Aalborg</city>
      <country>Denmark</country>
      <zip>9000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">an.larsson@nja.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52508">
    <organisation>Anaesthesia and Intensive Care Medicine of North Denmark Region (Denmark) </organisation>
    <website>http://www.an.rn.dk</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Soendre Skovvej 3, 2.</address>
      <city>Aalborg</city>
      <country>Denmark</country>
      <zip>9000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+45 993 28057</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ndn@rn.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425870.c</gridId>
    <rorId>https://ror.org/003gkfx86</rorId>
  </sponsor>
  <funder id="Funder16013-0">
    <name>Anaesthesia and Intensive Care Medicine of North Denmark Region (Denmark)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-13T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-02-13T00:00:00.000Z">53284852</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>HYbrid-Revascularisation In Senescent Cohorts: a prospective randomised comparative trial between minimally-invasive coronary revascularisation treatment without extra-corporeal circulation (off pump coronary surgery) and combined stent-implantation versus conventionally surgical treatment in cardioplegia with the aid of extra-corporeal circulation</title>
      <scientificTitle/>
      <acronym>HYRISC</acronym>
      <studyHypothesis>A decrease of postoperative rate of complications by hybrid-revascularisation is expected.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Occurrence of post-operative complications (organ insufficiencies, stroke, myocardial infarction, symptomatic transitory psychotic syndrome, infection, shock, multiple systems organ failure, death) during hospitalisation.</primaryOutcome>
      <secondaryOutcome>1. Lethality and therapy costs during hospitalisation and in the first post-operative year
2. Survival after six and 12 month
3. Rates of complications (see primary outcomes)
4. Post-operative quality of life (Short Form health survey [SF-36], Hospital Anxiety and Depression Scale [HADS])
5. Occurrence of postoperative complications in the group of  consecutive observed younger patients (control group)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Medical Faculty of the Martin-Luther-University Halle-Wittenberg, approval received on 23/02/2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN53284852</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>KKSH-018/1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="31a9a5c9-dba6-41a1-8a41-6d7f4c26199e">
	  <name>Universitätsklinik und Poliklinik für Herz- und Thoraxchirurgie</name>
	  <address/>
	  <city>Halle/Saale</city>
	  <state/>
	  <country>Germany</country>
	  <zip>06097</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Coronary heart disease with diseased Left Anterior Descending coronary artery (LAD) requiring surgery
2. Male or female patients with 75 years of age or older in therapy groups
3. Male or female patients with 60 years of age or less in consecutive observed younger patients (control group)
4. Signed and dated informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>459</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>459</totalTarget>
      <exclusion>1. Combined surgery (heart valve plus bypass)
2. Emergency treatment along with unstable cardiovascular system
3. Known intolerability of AcetylSalicylic acid (ASS), Clopidogrel and other concomitant medication required for stent-implantation
4. Participation on other clinical trials
5. Situations that limit the compliance with study requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multi-vessel coronary heart disease with diseased LAD requiring surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Hybrid group: surgical revascularisation of LAD with left Arteria thoracica interna-Bypass supply of dominant not interventional treatable vessels by off-pump technique.
2. Conventionally treated group: surgical revascularisation in cardioplegia by use of heart-lung machine.
3. Consecutive observed control group: surgical revascularisation in cardioplegia by use of heart-lung machine.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16018-0</funderId>
      <contactId>Contact53964_16018</contactId>
      <sponsorId>Sponsor52513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53964_16018">
    <title>Dr</title>
    <forename>Ivar</forename>
    <surname>Friedrich</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Universitätsklinik und Poliklinik für Herz- und Thoraxchirurgie
Ernst-Grube-Straße 40</address>
      <city>Halle/Saale</city>
      <country>Germany</country>
      <zip>06097</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ivar.friedrich@medizin.uni-halle.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52513">
    <organisation>Martin Luther-University Halle-Wittenberg (Germany)</organisation>
    <website>http://www2.uni-halle.de/index_e.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Universitätsklinik und Poliklinik für Herz- und Thoraxchirurgie
Ernst-Grube-Straße 40</address>
      <city>Halle/Saale</city>
      <country>Germany</country>
      <zip>06097</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ivar.friedrich@medizin.uni-halle.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9018.0</gridId>
    <rorId>https://ror.org/05gqaka33</rorId>
  </sponsor>
  <funder id="Funder16018-0">
    <name>Self-funded by the Department of Cardiothoracic Surgery and Cardiology, Martin-Luther-University Halle (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-08T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-02-08T00:00:00.000Z">82823121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An international, multicentre prospective single arm study to investigate procedural, clinical and angiographic outcomes using the Taxus Liberte stent, with improved side branch access, following the provisional side branch T-stenting approach, in patients with complex lesions</title>
      <scientificTitle/>
      <acronym>LIBERTY ONE</acronym>
      <studyHypothesis>The purpose of the LibertÉ One study is to assess procedural, clinical and angiographic outcomes of the provisional T-stenting approach with the Taxus Liberte stent implanted in complex lesions (with side branch involvement). The Taxus Liberte stent has larger cell perimeters and as such an improved side branch access.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Target lesion revascularisation of the main branch and side branch defined by the independent core lab at nine months follow-up.</primaryOutcome>
      <secondaryOutcome>1. Incidence of Major Adverse Cardiac Events (MACE) defined as all cardiac deaths, Q-wave and non-Q wave myocardial infarction, target lesion revascularisation (defined as both the main and the side branch) including Percutaneous Transluminal Coronary Angioplasty (PTCA) and Coronary-Artery Bypass Grafting (CABG) at one, seven, nine and 12 months follow-up
2. Acute success rate of stent delivery, recross, and final kissing balloon dilatation, and the number of a second stent implanted on the side branch
3. Restenosis will be evaluated by compulsory nine months angiogram using the binary definition (greater than 50% in diameter) in the main and the side branch vessel. Measure of the absolute lumen diameter will occur before, immediately after and at nine months, reflecting the net gain, difference of acute gain and late loss ratio and late loss index. Additional usual and lesion specific (main and side branch) quantitative results will be analysed
4. Target lesion and target vessel revascularisation of the main and side branch separately at seven, nine and 12 months follow-up</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82823121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>International, multicentre prospective single arm study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23d7f354-f82c-483e-9968-b3226862f4e4">
	  <name>Boston Scientific</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6201 BJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with stable angina pectoris (CCSC1234) or unstable angina and documented ischaemia or silent ischaemia
2. Patient eligible for coronary revascularisation
3. The target lesion has a major native coronary artery (more than 2.5 mm) with a stenosis more than 50% (on visual assessment) located at a side branch (more than 2 mm)
4. A de novo lesion
5. All angle severities (between branches) accepted
6. The main vessel lesion can be covered by one stent (up to 32 mm)
7. Other lesions in different vessels are successfully treated before the treatment of the target lesion (residual stenosis less than 30%, stent well deployed, no residual dissection, normal Thrombolysis in Myocardial Infarction [TIMI] flow, no chest pain, ElectroCardioGram [ECG] unchanged compared to pre-procedural ECG)
8. Only one target lesion can be included in the study
9. Signed patients informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>1. Patients with in stent restenosis of target lesion
2. Severe calcifications with an undilatable lesion during balloon predilatation (Percutaneous Transluminal Renal Angioplasty [PTRA] could be considered)
3. History of bleeding diathesis
4. Untreated significant lesion greater than 50% diameter stenosis remaining proximal or distal to the target intervention
5. Patient has suffered a stroke or Transient Ischaemic Attack (TIA) within the past six months
6. Known untreatable malignancy
7. Any major surgery planned or required during the next nine months
8. Acute myocardial infarction
9. Allergy to contrast and/or required antiplatelet medication
10. Left main coronary artery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary lesions</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Lesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Percutaneous Coronary Intervention (PCI), provisional side branch T-stenting.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16146-0</funderId>
      <contactId>Contact54092_16146</contactId>
      <sponsorId>Sponsor52647</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54092_16146">
    <title>Dr</title>
    <forename>Luc </forename>
    <surname>Verhees</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Boston Scientific
Gaetano Martinolaan 50</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6201 BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">luc.Verhees@bsci.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52647">
    <organisation>New Nantes Private Clinics (Nouvelles Cliniques Nantaises) (France)</organisation>
    <website>http://www.ncn.fr/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Unit of Care and Interventional Cardiology (UnitÉ de soins et de cardiologie interventionnelle)
4, rue Eric Tabarly</address>
      <city>Nantes</city>
      <country>France</country>
      <zip>44277</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">brunel-phiippe@wanadoo.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452749.9</gridId>
    <rorId>https://ror.org/03731ze76</rorId>
  </sponsor>
  <funder id="Funder16146-0">
    <name>Boston Scientific (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-01T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-02-01T00:00:00.000Z">21151711</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of loneliness and depression in elderly nursing home patients living in Amsterdam using life review therapy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Life review therapy will have a positive effect on the level of depressive symptoms of nursing home inhabitants.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Depression (GDS-8, MINI-interview) and loneliness (De Jong Gierveld Loneliness Scale)
2. Anxiety, HADS, autobiographical memory (AMT)

Post-treatment one or two weeks after ending intervention (four weeks after inclusion).</primaryOutcome>
      <secondaryOutcome>Analysing the influence of covariates on the outcome of the life review therapy (neuroticism [NEO-FFI], worrying [PSWQ-11], quality of life)/mastery (PMS).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21151711</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a8630c47-8138-4d01-81d4-7f4c2684b098">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 65
2. Living in a nursing home
3. Normal cognitive functioning/no signs of dementia
4. No pharmacological treatment</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. No or less depressive symptoms
2. Mild or severe cognitive symptoms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depressive symptoms</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 
The life review consisted of autobiographical retrieval practice that entailed focusing on a particular life period each week - childhood, adolescence, adulthood, and summary. For each period 14 quesions were asked that were designed to prompt specific memories. Examples of questions include ''What did your mother or father do one day when you were a child that astonished you?''.

Intervention sessions were tape-recorded and were scored by a psychologist. At pre- and post-test the following questionnaires were administered:
1. Depressive symptoms (eight-item Geriatric Depression Scale [GDS-8])
2. Cognitive functioning (Mini Mental State Examination [MMSE])
3. Mini International Neuropsychiatric Interview (MINI) (Diagnostic and Statistical Manual of mental disorders [DSM] diagnoses depression and dysthymia)
4. Anxiety (Hamilton Anxiety and Depression Scale [HADS])
5. Loneliness (De Jong Gierveld Loneliness Scale)
6. Autobiographical Memory Test (AMT)
7. Worrying (Penn State Worry Questionnaire [PSWQ])
8. Neuroticism (Neuroticism-Extraversion-Openness Five-Factor Inventory [NEO-FFI]-subscale)
9. Quality of life (Dutch Scale for Subjective well-being of the elderly [SSWO], short Portable Mental Status (PMS) questionnaire, ''balans opmaken vragenlijst'')

Control: 
Waiting list (after three months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16117-0</funderId>
      <contactId>Contact54063_16117</contactId>
      <sponsorId>Sponsor52617</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54063_16117">
    <title>Dr</title>
    <forename>Bas</forename>
    <surname>Steunenberg </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Department of Clinical Psychology
Van der Boechorststraat 1</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 598 8703</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">B.Steunenberg@psy.vu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52617">
    <organisation>VU University Medical Centre (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Clinical Psychology
Van der Boechorststraat 1</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16117-0">
    <name>Stichting Nuts Ohra (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-02-01T00:00:00.000Z">75611179</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of epidermal growth factor receptor inhibition on pulmonary arterial hypertension associated with systemic sclerosis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>As Epidermal Growth Factor Receptor (EGFR) plays a role in pathogenesis of both pulmonary arterial hypertension and systemic sclerosis, EGFR inhibition will lead to beneficial effects in disease course.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety: recorded by assessment and documentation in the Case Report Form (CRF) file of adverse events and toxicity (physical examination [with special attention to skin toxicity], laboratory data) at pre-treatment, treatment visits (week one to 12), and follow-up (six months, 12 months).</primaryOutcome>
      <secondaryOutcome>Efficacy: measured by effects on six minute walk test, stroke volume, changes in High Resolution Computed Tomography (HRCT), N-Terminal B-type Natriuretic Peptide (NT-pro-BNP).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethics Review Committee of VU University Medical Centre.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75611179</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>155/2006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II study, open-labelled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a526f5cf-e98a-4ba7-93e8-9071857643b4">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>A subject is eligible for inclusion in this study only if all of the following criteria apply:
1. Written informed consent
2. Systemic sclerosis
3. Pulmonary Arterial Hypertension (PAH) with a mean Pulmonary Arterial Pressure (PAP) of above 25 mmHg measured during rest
4. Pulmonary Vascular Resistance (PVR) above 300 dynes
5. Total Lung Capacity (TLC) more than 70%
6. New York Heart Association (NYHA) class III and/or six-Minute Walk Test (6-MWT) less than 80% predicted
7.Conventional PAH treatment and/or bosentan and/or sildenafil treatment
8. Stability on medication during the previous three months (defined as stable or decrease of 6-MWT after three months of treatment)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>A subject will be excluded from this study in case of the following criteria:
1. Left ventricular dysfunction
2. Valvular heart disease
3. Pericardial constriction
4. Wedge pressure more than or equal to 15 mmHg
5. Chronic thromboembolic pulmonary hypertension
6. Uncontrolled sleep apnea
7. History of malignancies
8. Overt right heart failure
9. History or presence of skin ulcerations
10. Women Of Child-Bearing potential (WOCB) who are unwilling or unable to use contraceptives
11. Sexually active fertile man not using effective birth control if their partners are WOCB
12. Severe abnormality of the cornea
13. Inadequate haematologic function defined by an absolute neutrophil count less than 1,500/mm^3, platelet count less than 80,000/mm^3 and haemoblobin level of less than 9 g/dL
14. Inadequate hepatic function defined by a total bilirubin level 1.5 times the Upper Limit of Normal (ULN) and ASpartate AminoTransferase (ASAT) levels 2.5 times ULN
15. Inadequate renal function defined by a serum creatinine level more than 1.5 times ULN (alternative: Cockroft less than 50 ml/min)
16. Substances that inhibit CYP3A4 activity, such as rifampicin, phenytoin, ketoconazole, itraconazole</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sclerosis-associated Pulmonary Arterial Hypertension (SScPAH)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Pulmonary Arterial Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All participants will receive cetuximab at a loading dose of 400 mg/m^2 in week one, followed by a weekly dose of 250 mg/m^2 starting from week two, up to a total of 12 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Cetuximab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16118-0</funderId>
      <contactId>Contact54064_16118</contactId>
      <sponsorId>Sponsor52618</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54064_16118">
    <title>Dr</title>
    <forename>A</forename>
    <surname>Boonstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Department of Pulmonary Diseases
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 4782</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.boonstra@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52618">
    <organisation>VU University Medical Centre (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/#http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16118-0">
    <name>VU University Medical Center (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-01-26T00:00:00.000Z">70791258</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Idiopathic membranous nephropathy is one of the most common causes of the nephrotic syndrome in adults. It leads to end-stage renal disease in roughly half of the patients. The disease is characterised by glomerular, subepithelial deposits which consist of immune complexes.

The hypothesis was that treatment with Adrenocorticotropic Hormone (ACTH) is superior to no specific treatment in nephrotic patients with idiopathic membranous nephropathy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes were complete remissions and the combination of complete and partial remissions at the end of the treatment period (nine months after study start) and at the end of the follow-up period (21 months after study start).

A complete remission was defined as urinary albumin excretion less than 200 mg/24 hours and a partial remission was defined as urinary albumin excretion less than 2000 mg/24 hours in combination with a reduction of at least 50%.</primaryOutcome>
      <secondaryOutcome>The secondary outcomes were the changes at the end of the treatment period and the end of the follow-up period, as compared to baseline, in the serum concentrations of albumin, creatinine, apolipoprotein A1, apolipoprotein B and lipoprotein(a), the urinary excretion/24 hours of albumin, immunoglobulin G and protein HC, glomerular filtration rate and mean arterial pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was accepted by the Ethics Committees in Lund, Sweden (ref: LU 183-99) and Gothenburg, Sweden (ref: Gbg M056-99). The date of final acceptance was May 18, 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70791258</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, controlled, open-label interventional study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-07-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e8727fa0-8848-4275-9b96-1f3cff0e9f94">
	  <name>Department of Nephrology</name>
	  <address/>
	  <city>Lund</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>221 00</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males and females
2. Age 18 to 90
3. Membranous nephropathy according to kidney biopsy
4. Proteinuria of the nephrotic range for at least six months
5. Treatment with a statin and an angiotensin converting enzyme inhibitor for at least three months
6. Urinary albumin excretion more than 3000 mg/24 hours
7. Serum albumin concentration less than 26 g/L</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Thirty</totalTarget>
      <exclusion>1. Moderate or heavy tubulointerstitial changes in the kidney biopsy
2. A recognisable cause of the nephrotic syndrome
3. Previous immunosuppressive treatment for the membranous nephropathy
4. Allergy to Synacthen Depot
5. Severe psychiatric disease
6. Pregnancy
7. History of noncompliance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-07-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Idiopathic membranous nephropathy</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Nephropathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants were randomised to treatment with Synacthen Depot or no specific treatment. Synacthen Depot is a depot preparation of a synthetic fragment of ACTH. The fragment consists of the first 24 amino acids of the native human peptide and it retains the adrenal activity. ACTH is formed in the pituitary gland. Its main action is the stimulation of the production/secretion of cortisol. The cortisol released by the actual dose of Synacthen Depot is not enough to explain an effect on membranous nephropathy. Thus, the mechanism of such an effect is unknown.

The dosage scheme of Synacthen Depot given subcutaneously was as follows: 
Month one: 1.0 mg once a week
Month two: 0.75 mg twice a week
Months three to six: 1.0 mg twice a week
Month seven: 0.75 mg twice a week  
Month eight: 1.0 mg once a week  
Month nine: 0.5 mg once a week</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Adrenocorticotropic Hormone (ACTH) in the form of Synacthen Depot</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15890-0</funderId>
      <funderId>Funder15890-1</funderId>
      <funderId>Funder15890-2</funderId>
      <funderId>Funder15890-3</funderId>
      <contactId>Contact53831_15890</contactId>
      <sponsorId>Sponsor52385</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53831_15890">
    <title>Dr</title>
    <forename>Anna-Lena</forename>
    <surname>Berg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nephrology
University Hospital in Lund</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>221 00</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)46 17 22 57</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Anna-Lena.Berg@njur.lu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52385">
    <organisation>Department of Nephrology, University Hospital in Lund (Sweden)</organisation>
    <website>http://www.skane.se/templates/Page.aspx?id=109334</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Getingevägen 4</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>221 00</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0) 46 17 12 47</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kerstin.wihlborg@med.lu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4514.4</gridId>
    <rorId>https://ror.org/012a77v79</rorId>
  </sponsor>
  <funder id="Funder15890-0">
    <name>The Department of Medicine of the University in Lund (Sweden) (ref: M: B 39 422/01, M: B 19 1036/03, M: B 1002/04)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15890-1">
    <name>The Federation of Swedish County Councils, Region Skane (Sweden) (ref: Lf 1297/00)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15890-2">
    <name>The Department of Nephrology, University Hospital in Lund (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15890-3">
    <name>The Department of Nephrology, Sahlgren´s University Hospital, Gothenburg (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-25T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-01-25T00:00:00.000Z">03187943</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluating comfort and handling of new patient extension line and bag connector for Peritoneal Dialysis (PD). A short-term, open controlled study.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluate patient satisfaction in a first filed utilisation before final desicion on product design.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patient satisfaction on handling by comparing current system with new system, twist.</primaryOutcome>
      <secondaryOutcome>Collect safety data on new patient line.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee at San Marino University Hospital in Genova , approved on 19/07/2006, ref: 0037753/06</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03187943</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1443</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, controlled, single center, comparative prospective pilot study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-22T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41261ec4-421d-4797-90c0-21cad70e0e7a">
	  <name>Gambro</name>
	  <address/>
	  <city>Mölndal</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-431 37</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients suffering from chronic renal failure
2. Age 18 years or older
3. Treated in a Continuous Ambulatory Peritoneal Dialysis (CAPD) program with Gambrosol trio (GEM 20U03 Ca 2,5)
4. Treated on CAPD for at least 24 months
5. Signed written informed consent to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>5</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>5</totalTarget>
      <exclusion>1. Pregnancy
2. HIV
3. Hepatitis
4. Participation in other studies during the study period if considered to cause interference with either of the studies
5. Treated in a haemodialysis program, patients with diagnosed abdominal pain not related with PD solution
6. Patients on night Automated Peritoneal Dialysis (APD)
7. Peritonitis within one month prior to the study
8. Presence of exit-site/tunnel infection or ongoing peritonitis
9. Impaired and /or disabled patients</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-22T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ESRD - End Stage Renal Disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal Disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Tested  products:  twist extension line combined with twist female connector on Gambrosol trio.

Reference products: current patient line (PDL 1201-8) and current Gambro CAPD system.
All patients will be treated in a CAPD program exchangning Gambrosol trio GEM 20U03 Ca 2,5 with twist for 3 to 5 exchanges/day following their physician's prescription on glucose concentration to be used. Evaluation on patient satisfaction will be done with a questionnaire at three times: before switch to twist, after two weeks on twist and at four weeks on tested products (end of study).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16039-0</funderId>
      <contactId>Contact53985_16039</contactId>
      <sponsorId>Sponsor52534</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53985_16039">
    <title>Mrs</title>
    <forename>Christina</forename>
    <surname>Schönborg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gambro
Clinical Affairs
Krokslätts Fabriker 32</address>
      <city>Mölndal</city>
      <country>Sweden</country>
      <zip>SE-431 37</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52534">
    <organisation>Gambro (Sweden)</organisation>
    <website>http://www.gambro.com/start.aspx?id=752</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Affairs
Emdalavägen 5
P.O. Box 10101
</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>SE 220 10 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420188.7</gridId>
    <rorId>https://ror.org/05mw5ed57</rorId>
  </sponsor>
  <funder id="Funder16039-0">
    <name>Gambro (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-24T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-01-22T00:00:00.000Z">07286192</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of post-traumatic stress disorder in children and adolescents</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Risk of chronic Post-Traumatic Stress Disorder (PTSD) after Acute Stress Disorder (ASD) diminishes with an early intervention (Cognitive Behavioural Therapy [CBT]) that attempts to modify cognitive appraisals.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Presence versus absence of PTSD
2. PTSD-symptom-severity, assessed with:
a. structured interview (Anxiety Disorders Interview Schedule for Children [ADIS-C])
b. self-completed questionnaires (Child Post-traumatic Stress Scale [CPSS])</primaryOutcome>
      <secondaryOutcome>Symptoms of anxiety and/or depression according to questionnaires (Revised Children's Anxiety and Depression Scale [RCADS]) and quality of life.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethics Commission academic hospital of Maastricht/Maastricht University (Medisch Ethische Commissie azM/UM) on the 11th OCtober 2006 (ref: 06-3-045).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07286192</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, crossover, single blind multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="452b8437-65f2-46a1-a0d2-e9d4e5cd420e">
	  <name>University Maastricht</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6200 MD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children (aged seven to 17) 
2. Had contact with Victim Assistance experiencing a traumatic event less than two weeks ago
3. Meet the Diagnostic and Statistical Manual of mental disorders (DSM) criteria for Acute Stress Disorder</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="7.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Brain injury
2. Psychotic or organic mental disorder
3. Current suicidal ideation
4. Intelligence Quotient (IQ) less than 80
5. Low proficiency in Dutch
6. No parent willing to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-Traumatic Stress Disorder (PTSD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Stress</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Brief trauma-focused cognitive behavioral therapy intervention or control-condition (wait-list-controls).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16084-0</funderId>
      <contactId>Contact54030_16084</contactId>
      <sponsorId>Sponsor52582</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54030_16084">
    <title>Dr</title>
    <forename>Manon J B</forename>
    <surname>Vincken</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Maastricht
Department of Medical, Clinical and Experimental Psychology
P.O. Box 616</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6200 MD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)43 388 1047</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.vincken@dmkep.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52582">
    <organisation>University Maastricht (UM) (The Netherlands)</organisation>
    <website>http://www.unimaas.nl/default.asp?taal=en</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 616</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6200 MD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5012.6</gridId>
    <rorId>https://ror.org/02jz4aj89</rorId>
  </sponsor>
  <funder id="Funder16084-0">
    <name>Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001826</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-01-22T00:00:00.000Z">28587216</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Feasibility and safety of inhaled heparin in intubated and mechanically ventilated patients: a randomised controlled trial comparing three doses of inhaled unfractionated heparin</title>
      <scientificTitle/>
      <acronym>NebHep study</acronym>
      <studyHypothesis>We hypothesise that unfractionated heparin could be of benefit in treatment of Acute Lung Injury (ALI). Delivering heparin directly to the pulmonary compartment may attenuate fibrin depositions more effectively while reducing the risk of bleeding as a result of systemic anticoagulant effects. Intubated and mechanically ventilated patients may also benefit from such strategies since mechanical ventilation may cause injury very similar to ALI and pneumonia.

Before future investigations of therapeutic effects of nebulised unfractionated heparin in mechanically ventilated patients with ALI can be performed, this therapeutic strategy needs to be tested on its feasibility and safety. Therefore, in this study we will evaluate the feasibility and safety of treatment with inhaled heparin in intubated and mechanically ventilated patients without ALI. We consider treatment with inhaled heparin to be safe if none of the included patients show a more than 25% increase of area under the curve of serial anti-Xa measurements in plasma. 
If treatment with inhaled heparin is safe, we will perform a new study in patients with ALI.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Area under the curve of serial anti-Xa measurements in plasma.</primaryOutcome>
      <secondaryOutcome>1. Blood:
a.  Area under the cure of serial aPTT measurements
b. Whole blood clotting time lung fluid:
area under the curve of serial anti-Xa  measurements, heparin, factor VII/VIIa, Tissue Factor (TF), Tissue Factor Pathway Inhibitor (TFPI)-antigen, TFPI activity, protein C/activated protein C, prothrombin fragment 1.2, Thrombin-AntiThrombin III complex (TATc), Endogenous Thrombin Potential (ETP), Fibrin monomers, soluble thrombomodulin, Plasmin-AntiPlasmin complexes (PAPc), Plasminogen Activator Inhibitor (PAI)
2. Occurrence and severity of bleeding events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28587216</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a081ffb4-f854-4a22-bdf8-aff6f2d7ecf8">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients who are mechanically ventilated
2. Aged more than 18 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Acute Lung Injury (consensus criteria)
2. Increased risk of bleeding:
a. Within 24 hours after major surgery
b. Thrombocytes less than 50 x 10^9/L
c. Prothrombin Time (PT) more than 20 seconds
d. Activated Partial Thromboplastin Time (APTT) more than 60 secconds
3. Acute bleeding at any site
4. Pregnancy or breast feeding</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mechanical ventilation</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory distress</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of unfractionated heparin or placebo by aerosol generator (AeronebPro, Aerogen Inc., Sunnyvale, CA, USA) during mechanical ventilation. 

Blood samples and lung fluid will be collected before treatment and at one, three, six and 24 hours after the beginning of the last nebulisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Unfractionated heparin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16083-0</funderId>
      <contactId>Contact54029_16083</contactId>
      <sponsorId>Sponsor52581</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54029_16083">
    <title>Dr</title>
    <forename>J J</forename>
    <surname>Hofstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
IC Unit
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31(0)20 566 8224</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">J.J.Hofstra@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52581">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl/#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16083-0">
    <name>Academic Medical Center (AMC) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003180</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-16T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-01-16T00:00:00.000Z">26286159</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>TUmor Necrosis factor blockaDe in patients with Rheumatoid Arthritis inhibits atherothrombosis</title>
      <scientificTitle/>
      <acronym>TUNDRA</acronym>
      <studyHypothesis>In the current study we aim to establish whether Tumor Necrosis Factor (TNF)-alpha plays a central role in inflammation-mediated acceleration of atherogenesis and the propencity towards development of atherothrombotic disease in Rheumatoid Arthritis (RA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Endothelial Function (Flow-Mediated Dilation [FMD])
2. Glycocalyx

Before treatment, zero to four weeks after treatment, nine to 12 weeks after treatment.</primaryOutcome>
      <secondaryOutcome>1. Atherosclerosis: Plasma:
a. total cholesterol
b. Low Density Lipoproteins [LDL]
c. High Density Lipoproteins [HDL]
d. Triglycerides
e. Lipoprotein a [Lp(a)]
f. oxidised LDL
2. Thrombosis:
1. D-dimer
2. prothrombin fragment 1 and 2 (F1+2)
3. soluble Tissue Factor (sTF)
4. Plasminogen Activator Inhibitor type 1 (PAI-1)
3. Inflammation:
a. InterLeukin-1beta (IL-1beta)
b. TNF-alpha
c. InterLeukin 6 (IL-6)
d. InterLeukin-8 (IL-8)
e. Interleukin 10 (IL-10)
f. high-sensitivity C-Reactive Protein (hsCRP)

Before treatment, zero to four weeks after treatment, nine to 12 weeks after treatment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26286159</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>This is an observational study in RA patients undergoing therapy with TNF-alpha blockade</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a93b3b76-f46a-400e-bb0e-b563f1d1ab97">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female patients who were priorly diagnosed with RA, who are currently experiencing an inflammatory episode and who will be treated with TNF-alpha blockade
2. Age 18 to 80 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>1. Patients who were priorly diagnosed with diabetes, hypertension or cardiovascular disease
2. Current signs or symptoms of severe, progressive or uncontrolled hepatic, haematological, gastroenterological, endocrine, pulmonary, cardiac or neurological disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>TNF-alpha blockade (patients are their own control).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16046-0</funderId>
      <contactId>Contact53992_16046</contactId>
      <sponsorId>Sponsor52541</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53992_16046">
    <title>Dr</title>
    <forename>Sander</forename>
    <surname>van Leuven</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Vascular Medicine
Room F4-159.2
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 8675</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.i.vanleuven@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52541">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl/#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16046-0">
    <name>Academic Medical Center (AMC) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003180</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-05T00:00:00.000Z">80924721</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of proton pump inhibitor treatment on apnea severity in patients with laryngopharyngeal reflux and obstructive sleep apnea</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>In patients with mild to moderate Obstructive Sleep Apnea (OSA) and endoscopic evidence of laryngeal inflammation, proton pump inhibitor treatment will lead to an improvement in apnea severity and apnea-related symptoms.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in apnea-hypopnea index from baseline to six months.</primaryOutcome>
      <secondaryOutcome>1. Laryngoscopic Reflux Finding Score
2. Laryngeal air pressure pulse sensory threshold
3. Reflux Symptom Index
4. Epworth Sleepiness Score
5. Quebec Sleep Apnea Quality of Life Index
6. Functional Outcomes of Sleep instrument 

All at baseline, four and six months; also Polysomnographic variables other than apnea-hypopnea Index at baseline and six months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>McGill University Health Centre Research Ethics Board (Study No. BMA 05-018), approved January 24, 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80924721</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled trial, single-blinded: drug versus no-drug.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c00de632-e5f2-418e-912a-178af4b89790">
	  <name>McGill University Health Centre</name>
	  <address/>
	  <city>Montreal, Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3A 1A1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults 20 to 70 years with untreated obstructive sleep apnea,  non-smoking
2. Epworth sleepiness score less than 15
3. Apnea-hypopnea index of 15 to 60 events per hour, with Non-Rapid Eye Movement Apnea Hypopnea Index (NREM AHI) more than 10, nadir Saturation of Oxygen in arterial blood (SaO2) more than or equal to 80% at overnight polysomnography
4. Reflux Finding Score more than 7 on laryngoscopy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44 (22 per group)</totalTarget>
      <exclusion>1. Any prior treatment for OSA
2. Current or past proton pump inhibitor therapy, current inhaled or systemic corticosteroid, or systemic immunosuppressive treatment
3. Active cardiovascular disease (uncontrolled hypertension, unstable angina, myocardial infarction within the preceding six months, congestive heart failure)
4. Epworth Sleepiness Score more than 15 or employment in a safety critical position regardless of Epworth Score
5. History of a bleeding disorder
6. Otolaryngologic conditions including glottic or subglottic stenosis, cancer of the larynx,   previous radiotherapy, upper airway surgery other than remote tonsillectomy, or major craniofacial malformation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive Sleep Apnea</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Involuntary closing of the muscles of the throat</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Six month treatment with Lansoprazole 30 mg orally twice a day (BID) or no drug.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lansoprazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15759-0</funderId>
      <funderId>Funder15759-1</funderId>
      <contactId>Contact53697_15759</contactId>
      <sponsorId>Sponsor52251</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53697_15759">
    <title>Dr</title>
    <forename>Richard John</forename>
    <surname>Kimoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>McGill University Health Centre
Room L4.08
687 Pine Ave W</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H3A 1A1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514-934-1934, ext. 36117</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">john.kimoff@muhc.mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52251">
    <organisation>McGill University Health Centre Research Institute (Canada)</organisation>
    <website>http://www.muhc.ca/research</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>1650 Cedar Ave
Room A6.141</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H3G 1A4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514-934-1934 ext. 44580</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lynn.derycapes@muhc.mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.63984.30</gridId>
    <rorId>https://ror.org/04cpxjv19</rorId>
  </sponsor>
  <funder id="Funder15759-0">
    <name>Operating funds provided by the Sponsor: MUHC Research Institute (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15759-1">
    <name>Study drug, but no operating or other funds provided by Abbott Laboratories (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-04T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">60878792</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the effect of a follow-up program forSMOcessation courses during in-patient REHAbilitation treatment</title>
      <scientificTitle/>
      <acronym>ESMOREHA</acronym>
      <studyHypothesis>1. Patients who complete intensive follow-up programs more frequently quit or reduce their smoking than those without such an intervention.
2. The smoking cessation program in Borkum is at least as successful as comparable programs.
3. The quit date method leads to a higher long-therm outcome relative to nicotine abstinence.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reduction of the risk of nicotine-associated illness.</primaryOutcome>
      <secondaryOutcome>1. Quality of life improvement
2. Reduction in direct and indirect costs</secondaryOutcome>
      <trialWebsite>http://www.refonet.de/projekte/laufendeprojekte_3014.php</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Medical Association of Lower Saxony Germany, approval received on the 22nd September 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60878792</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, prospective, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e5056cd5-1b8a-48a4-90d9-4a6fa05bacb7">
	  <name>Bubertstr.4</name>
	  <address/>
	  <city>Borkum</city>
	  <state/>
	  <country>Germany</country>
	  <zip>26757</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients of the Nordseeklinik
2. Funded by the Deutsche Rentenversicherung Rheinland
3. Patients who are older than 18</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>580</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>580</totalTarget>
      <exclusion>1. Patients who are younger than 18
2. Linguistic or intellectual deficits
3. Missing agreement</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking addiction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Smoking addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Follow-up reminder calls and refresher courses for 12 months versus care as usual.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15310-0</funderId>
      <contactId>Contact53224_15310</contactId>
      <sponsorId>Sponsor51769</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53224_15310">
    <title>Dr</title>
    <forename>Jörg</forename>
    <surname>Resler</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bubertstr.4</address>
      <city>Borkum</city>
      <country>Germany</country>
      <zip>26757</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 4922/9212000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joerg.resler@nordseeklinik-borkum.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51769">
    <organisation>Refonet (Germany)</organisation>
    <website>http://www.refonet.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>53445</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 264 190620</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">service@refonet.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder15310-0">
    <name>Refonet (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-04T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">38944269</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacological modulation of heterosynaptic LOng-TErm POtentiation in humans by ONdansetron and DExtromethorphan</title>
      <scientificTitle/>
      <acronym>LOTEPODEON (LOng-TErm POtentiation DExtromethorphan ONdansetron)</acronym>
      <studyHypothesis>Long-Term Potentiation (LTP) within the nociceptive system is one of the mechanisms underlying central sensitisation, which accounts for some hyperalgesic pain states in chronic pain patients. In the study we will use a human surrogate model of nociceptive LTP to study the involvement of NMDA-receptors and 5-HT3-receptors in the induction of hyperalgesia following high-frequency electrical stimulation of nociceptive afferents in the skin.

We will study the contribution of NMDA- and 5-HT3 receptors in plastic changes within the nociceptive system, which occur typically after a tissue injury, but in contrast to a real lesion we mimic an injury by high-frequency electrical stimulation of nociceptive afferents in the skin. This conditioning stimulation will lead to pain to light tactile stimuli (dynamic mechanical allodynia) and to an increase of pain to punctuate mechanical pain stimuli (static mechanical hyperalgesia). Both phenomena can typically been found in a subset of neuropathic pain patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Spread of the area of dynamic allodynia and static hyperalgesia
2. Combined analgesic and anti-hyperalgesic effect to mechancial and electrical stimuli on the site of conditioning stimulation</primaryOutcome>
      <secondaryOutcome>1. Anti-hyperalgesic effect to electrical and mechanical test stimuli 
2. Analgesic effect to electrical and mechanical test stimuli 
3. Anti-wind up</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethics committee (Ethikkommission der Landesärztekammer Rheinland-Pfalz; 15th March, 2003, reference number: 837.002.03(3664)) and was conducted in accordance with the declaration of Helsinki, the German Medicines Act (AMG), and the guidelines of the International Conference on Harmonisation (ICH) for Good Clinical Practice (GCP).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38944269</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Tr 236/16-2/LTP-Ondan-Dex</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The trial was designed as a double blind, randomised and placebo-controlled three-way cross-over study (Placebo-Dextromethrophan-Ondansetron).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6ad2442e-6d58-4837-bf57-872ceff43e92">
	  <name>Institute of Physiology and Pathophysiology</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>55128</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers of full age
2. Subject familiarised with the experimental procedure prior to experimentation and had given written informed consent
3. At least a 50% increase of pain to pinprick stimuli and a 25% increase of pain to electrical stimuli following high-frequency electrical stimulation in a screening visit</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>18</totalTarget>
      <exclusion>1. Skin lesions at the test and/or control site
2. Use of any medication within one day prior to study onset except contraceptives
3. Known hypersensitivity to histamine or to dextromethorphan and ondansetron and their derivates
4. Any history of allergy or drug hypersensitivity
5. Chronic use of analgesics or Central Nervous System (CNS) active drugs
6. Pregnancy or nursing
7. Any acute or chronic disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperalgesic pain states in chronic pain patients</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Chronic pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The effect of 150 mg dextromethorphan and 16 mg ondansetron orally (p.o.) will be compared to placebo in a three-way cross-over design. Sensory changes will be determined by Quantitative Sensory Testing (QST) using non-nociceptive and low-intensity painful mechanical and electrical stimuli.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dextromethrophan and Ondansetron</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15779-0</funderId>
      <contactId>Contact53719_15779</contactId>
      <sponsorId>Sponsor52271</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53719_15779">
    <title>Prof</title>
    <forename>Rolf-Detlef</forename>
    <surname>Treede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Physiology and Pathophysiology
Johannes Gutenberg-University Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52271">
    <organisation>Individual Sponsor (Germany)</organisation>
    <website/>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>Prof. Dr. Rolf-Detlef Treede
Institute of Physiology and Pathophysiology
Johannes Gutenberg-University Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)61313925715</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15779-0">
    <name>The study is supported by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft) (Germany) (Grant: Tr236/16-2)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-03T00:00:00.000Z">26390986</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Forced Use Aphasia Therapy in the ACute phase</title>
      <scientificTitle/>
      <acronym>FUATAC</acronym>
      <studyHypothesis>1. Forced Use Aphasia Therapy (FUAT) leads to significant improvements in language skills.
2. FUAT is more effective than &#145;classical&#146; aphasia therapy. 
3. Comparable significant improvements in language skills are reached earlier in FUAT.
4. Effects of treatment can be found in both FUAT-group and control group at six months post treatment.
5. Improvements in language skills will also improve communication skills, with FUAT being more effective.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To establish efficacy of FUAT in the acute phase</primaryOutcome>
      <secondaryOutcome>1. To establish efficiency of FUAT as compared to standardised aphasia therapy. 
2. To establish long-term effects of aphasia therapy (both FUAT and standard)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethik-Kommission of Medizinische Fakultät Bonn (Germany), date of approval: 09/08/2006 (ref: 107/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26390986</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>05004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="24a16b6d-ef53-46f0-8b5d-77b730c79e53">
	  <name>NRZ Godeshoehe</name>
	  <address/>
	  <city>Bonn</city>
	  <state/>
	  <country>Germany</country>
	  <zip>53177</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Left hemispheric cerebro-vascular accident maximally three months post-onset
2. Aphasia (by clinical diagnosis and standardised aphasia screening)
3. Monolingual German native speaker</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>52</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>52</totalTarget>
      <exclusion>1. Aphasia mainly characterised by automatisms 
2. Severe jargon 
3. Severe apraxia of speech 
4. Severe neuropsychological and/or psychiatric disorders</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Aphasia</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Symptoms and signs involving speech and voice</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 
Forced-use aphasia therapy is characterised by various aspects:
1. Treatment is group treatment (two to three persons). 
2. Treament per day is three to four hours. 
3. Treatment is primarily based on communicative aspects. 

Control: 
In the control group the people with aphasia receive therapy as usual. Control patients will have individual sessions once a day, and therapy is focussed on language/linguistic skills. 

Both groups consist of 26 persons. The intervention will take place for six weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15865-0</funderId>
      <contactId>Contact53805_15865</contactId>
      <sponsorId>Sponsor52359</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53805_15865">
    <title>Dr</title>
    <forename>Jutta</forename>
    <surname>Küst</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>NRZ Godeshoehe
Waldstrasse 2-10</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53177</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.kuest@godeshoehe.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52359">
    <organisation>Refonet (Germany)</organisation>
    <website>http://www.refonet.de/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Dr H Pollmann
Postfach 10 07 63</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>53177</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2641 9062-12</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">service@refonet.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder15865-0">
    <name>Rehabilitations-Forschungsnetzwerk der DRV Rheinland (ReFonet) (Germany ) (Project Number: 05004).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-16T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">73817429</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study on Cost-Effectiveness of Personality disorder TREatment</title>
      <scientificTitle/>
      <acronym>SCEPTRE</acronym>
      <studyHypothesis>1. Effect sizes of the psychotherapeutic treatments vary between 0.5 and 2.0.
2. A lower dosage of psychotherapeutic treatment is mainly related to symptomatic improvement, while a higher dosage is also related to structural and functional improvement.
3. The dosage for an optimal cost-effectiveness is lower than the maximum dosage.
4. When compared to cluster B personality disorders, for cluster C personality disorders a lower dosage is required to reach optimal cost-effectiveness.
5. A lower level of psychological mindedness and/or ability for a positive working alliance with the therapist is related to a lower level of (cost)-effectiveness.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Structural improvement of personality pathology (assessed with the Outcome Questionnaire [OQ45], and the Severity Indices of Personality Problems [SIPP])
2. Quality Adjusted Life Years (QALYs)</primaryOutcome>
      <secondaryOutcome>1. Symptomatic improvement (assessed with the Symptoms CheckList [SCL-90])
2. Functional improvement (assessed with, amongst others, questions regarding work situation and care consumption)
3. Quality of life</secondaryOutcome>
      <trialWebsite>http://www.vispd.nl/projects.htm</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Research Ethics Committee (REC) of Erasmus Medical Centre, Rotterdam, on the 7th January 2004 (ref: MEC 229.834/2003/122).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73817429</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="875161d8-bb6b-4bf3-99ac-35516e539a00">
	  <name>Viersprong Institute for Studies on Personality Disorders (VISPD)</name>
	  <address/>
	  <city>Halsteren</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>4660 AA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. At least one Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) axis-II diagnosis
2. An indication for psychotherapeutic treatment aiming at structural improvement of the personality pathology (besides symptomatic and/or functional improvement)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>821</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>821</totalTarget>
      <exclusion>1. Insufficient command of Dutch language
2. Severe cognitive impairments
3. Mental retardation
4. Axis-I schizophrenia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Personality Disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Personality disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Psychotherapeutic treatment programs for patients with personality pathology that will be distinguished from one another according to the following dosages:
1. Short (maximum of six months) outpatient
2. Short day hospital
3. Short inpatient
4. Long (at least six months) outpatient
5. Long day hospital
6. Long inpatient</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15958-0</funderId>
      <contactId>Contact53904_15958</contactId>
      <sponsorId>Sponsor52453</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53904_15958">
    <title>Dr</title>
    <forename>Helene</forename>
    <surname>Andrea </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Viersprong Institute for Studies on Personality Disorders (VISPD)
P.O. Box 7</address>
      <city>Halsteren</city>
      <country>Netherlands</country>
      <zip>4660 AA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)16 463 2200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">helene.andrea@deviersprong.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52453">
    <organisation>Viersprong Institute for Studies on Personality Disorders (VISPD) (The Netherlands)</organisation>
    <website>http://www.vispd.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 7</address>
      <city>Halsteren</city>
      <country>Netherlands</country>
      <zip>4660 AA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487405.a</gridId>
    <rorId>https://ror.org/048jnwk41</rorId>
  </sponsor>
  <funder id="Funder15958-0">
    <name>Psychotherapeutic Center De Viersprong (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-16T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">46063747</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of long term administration of fluoxetine on cerebral threshold and muscle activation patterns in chronic stroke</title>
      <scientificTitle/>
      <acronym>flu2006</acronym>
      <studyHypothesis>1. Long term use of fluoxetine causes the excitability of the primary motor area of the brain to change
2. Long term administration of fluoxetine causes the muscle activation patterns to change</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Excitability of the primary motor area, measured by motor threshold and stimulus response curve
2. Muscle activation, measured by calculating Root Mean Square (RMS) during isometric and dynamic movements</primaryOutcome>
      <secondaryOutcome>1. Brain activation patterns
2. Phase synchronisation of the brain
3. Motor function</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethics committee of Medisch Spectrum Twente (Enschede, The Netherlands) on the 7th February 2007  (ref: P06-53).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46063747</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2458ac31-598d-4540-af39-11e5d4000b85">
	  <name>Rehabilitation Centre 'The Roessingh' Enschede</name>
	  <address/>
	  <city>Enschede</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>7500 AH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic ischaemic stroke patients (more than six months after stroke)
2. Aged over 18</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>28</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>28</totalTarget>
      <exclusion>1. Patients suffering from another neurological disease
2. Uncompensated hemineglect or cognitive disabilities
3. Epilepsy, or first epileptic insult post stroke
4. Patients with first grade relatives suffering from epilepsy
5. Pregnancy
6. Pacemaker
7. Pathological heart rhythms disorders
8. Use of anti-depressants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>20 mg of fluoxetine during 12 weeks versus placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluoxetine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15962-0</funderId>
      <funderId>Funder15962-1</funderId>
      <contactId>Contact53908_15962</contactId>
      <sponsorId>Sponsor52457</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53908_15962">
    <title>Dr</title>
    <forename>H I</forename>
    <surname>van Genderen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rehabilitation Centre 'The Roessingh' Enschede
P.O. Box 310</address>
      <city>Enschede</city>
      <country>Netherlands</country>
      <zip>7500 AH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)53 487 5765</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.vangenderen@rrd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52457">
    <organisation>Rehabilitation Centre 'The Roessingh' Enschede (The Netherlands)</organisation>
    <website>http://www.rrd.nl/www/indexa.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 310</address>
      <city>Enschede</city>
      <country>Netherlands</country>
      <zip>7500 AH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.ijzerman@utwente.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.491418.1</gridId>
    <rorId>https://ror.org/02nmj4h80</rorId>
  </sponsor>
  <funder id="Funder15962-0">
    <name>St. Jorisstichting (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15962-1">
    <name>Ridderlijke Duitsche Order (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-20T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">04371570</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Introduction and effects of structured drug counselling in the hospital</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The intervention will lead to: 
1. More knowledge about (the use of) prescibed medicines
2. A better use of medicines during the stay in the hospital and after discharge</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Difference in knowledge about prescribed medicines between intervention and control group at measurement II, per patient corrected for the basis at measurement I (method: questionnaires)
2. Differences in correct use of medicines between intervention and control group at measurement III (method: questionnaires)</primaryOutcome>
      <secondaryOutcome>1. Differences in spotting and reporting medication deviations during the distribution of medicines in hospital between intervention and control group (measurement II)
2. Differences in satisfaction about the received information about medicines (measurement II)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethics Review Committee, VU University Medical Centre Amsterdam on the 25th January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04371570</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c71bf732-4712-4754-afbe-48b9ac99bba8">
	  <name>VU Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Admission at one of the participating departments
2. Informed consent
3. Duration of admission at least three days maximally a month</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Patients younger than 18 years
2. Patients who are emotionally or physically not capable to participate
3. Senile dementia, confusion of the patient
4. Inability to express in Dutch language</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cancer, Lung disease</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Lung cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Personalised computer generated medication reminder charts during admission and discharge and brochures about specific medicines
2. Patient safety chart with instructions for safe and correct use of medicines
 
The intervention measurements at the departments of lung diseases and oncology lasts three months. The control measurements last three months (same departments).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15973-0</funderId>
      <funderId>Funder15973-1</funderId>
      <contactId>Contact53919_15973</contactId>
      <sponsorId>Sponsor52468</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53919_15973">
    <title>Dr</title>
    <forename>F A G</forename>
    <surname>Hout</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU Medical Center
Department of Public and Occupational Health/EMGO Institute
Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 9682</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.hout@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52468">
    <organisation>VU University Medical Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder15973-0">
    <name>Agis Health Insurance Company (Agis-zorgverzekering) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15973-1">
    <name>Dutch Association of Medical Specialists (Orde van Medisch Specialisten) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">08364639</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Performance of the miniaturo™-I system for treatment of overactive bladder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Urge incontinence is caused by overactivity of the detrusor muscle of the urinary bladder. Electrical stimulation of the pelvic floor muscles can suppress detrusor overactivity. The miniaturo™-I system is designed to deliver mild electrical stimulation to the pelvic floor muscles in a minimally invasive way.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in number of leaking episodes/day</primaryOutcome>
      <secondaryOutcome>1. Clinical success rate at three months, six months and 12 months
2. Number of serious adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08364639</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CP-01-017</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, interventional, feasibility study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="57a67c55-4e45-45e0-9652-8941828926fc">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Females more than 18 years
2. Failed conservative treatment for more than six months
3. Detrusor overactivity on urodynamic study
4. Urinary urge incontinence more than five episodes a day
5. Urinary frequency more than 10/day and more than 3/night
6. Competent sphincter mechanism
7. Normal upper tract
8. Passing MST-I session</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Participation in another study less than three months
2. Any active implant
3. Incontinence surgery less than three months
4. Spinal or genital surgery less than six months
5. Post void residual less than 100 ml
6. Leak point pressure more than 100 cm Water (H2O)
7. Pelvic pain syndrome
8. Stress incontinence
9. Cystocele/rectocele/enterocele grade three or four
10. Neurological disease
11. Morbid obesity
12. Severe uncontrolled diabetes
13. Severe heart disease
14. Requiring frequent Magnetic Resonance Imaging (MRI) exams
15. Pregnancy or attempt to get pregnant
16. Uncontrolled bleeding coagulopathy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urge incontinence</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Electrical stimulation of the pelvic floor muscles by an implantable electrical device.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15974-0</funderId>
      <contactId>Contact53920_15974</contactId>
      <sponsorId>Sponsor52469</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53920_15974">
    <title>Prof</title>
    <forename>J L H R</forename>
    <surname>Bosch</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
Department of Urology
Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52469">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Urology
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15974-0">
    <name>American Medical Systems, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-16T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-10-30T00:00:00.000Z">77598683</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of sustained acupressure in addition to group counselling and nicotine replacement therapy in a smoking cessation clinic: a pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pilot study: to test accrual, compliance, adverse events, outcome measures.
Underlying hypotheses: that acupuncture reduces either nicotine withdrawal symptoms and/or use of Nicotine Replacement Therapy (NRT).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Counts (accrual, use of beads, adverse events)
2. Mood and Physical Symptoms Scale 
3. NRT consumption</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval granted 8 March 2005 (reference: 04/Q2103/154).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77598683</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0184158213</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial with three arms.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3ddcad71-f2bf-4db2-80c2-6e90bdf32245">
	  <name>N32 ITTC Building</name>
	  <address/>
	  <city>Plymouth</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OK6 8BX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Smoke more than ten cigarettes/day
2. Were aged 18 years or over
3. Intended to stop smoking on the quit date
4. Chose NRT rather than bupropion
5. Gave informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. History of current otitis externa or other pathological condition of the ear
2. History of a poorly controlled relevant medical condition
3. Currently taking anti-depressant or anti-psychotic medication
4. History of allergy to adhesive dressing
5. Belief of pregnancy
6. Already participating in a research project</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking cessation</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Smoking cessation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Acupressure with two beads 
2. Acupressure with one bead 
3. No additional intervention

All participants receive standard intervention with group therapy and NRT.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nicotine replacement therapy</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17359519 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f1231973-91ed-4341-8f72-0f586acb04df" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-03-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17359519"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15396-0</funderId>
      <contactId>Contact53328_15396</contactId>
      <sponsorId>Sponsor51875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53328_15396">
    <title>Dr</title>
    <forename>Adrian</forename>
    <surname>White</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>N32 ITTC Building
Tamar Science Park</address>
      <city>Plymouth</city>
      <country>United Kingdom</country>
      <zip>OK6 8BX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1752 764448</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adrian.white@pms.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51875">
    <organisation>Peninsula Medical School (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Professor John Campbell
Smeall Building
St Luke's Campus</address>
      <city>Exeter</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>EX1 2LU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 1752 262740</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">john.campbell@pms.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.467855.d</gridId>
    <rorId>https://ror.org/04dtfyh05</rorId>
  </sponsor>
  <funder id="Funder15396-0">
    <name>Supported by the DH-National Co-ordinating Centre for Research Capacity Development (NCC RCD); and by the Smoking Advice Service, Plymouth PCT (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-04-26T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-10-19T00:00:00.000Z">07606792</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Esophageal Doppler guided fluid management Improves blood lactate clearance in multiple Trauma Patients: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>EDITP</acronym>
      <studyHypothesis>Early optimisation of intravascular volume using esophageal Doppler in comparison with standard haemodynamic management may in multiple trauma patients improve blood lactate clearance and reduce organ dysfunction development.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Blood lactate clearance after 12 and 24 hours after ICU admission 
2. Organ dysfunction development during ICU stay</primaryOutcome>
      <secondaryOutcome>1. Duration of ICU and hospital stay 
2. The incidence of infectious complications during ICU stay</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Local Research Ethics Committee of University Hospital in Plzen on 10/05/2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07606792</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional open randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-10-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Czech Republic</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ad378b11-cae6-4e21-910a-841d4080c89e">
	  <name>Anesthesiology and Intensive Care Department</name>
	  <address/>
	  <city>Plzen</city>
	  <state/>
	  <country>Czech Republic</country>
	  <zip>30460</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Ventilated patients with multiple trauma and estimated blood loss more than 2000 ml admitted to interdisciplinary Intensive Care Unit (ICU) of teaching university hospital in 2003 to 2005.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Target number of participants was 160</totalTarget>
      <exclusion>1. Patients aged less than 18 years
2. Patients with traumatic brain injury requiring treatment of intracranial hypertension
3. Those with relative contraindications to the use of the esophageal Doppler probe, such as orofacial and esophageal injury or other known oropharyngeal and esophageal disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-10-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multiple trauma patients</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Trauma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised into protocol or control group according to the assigned admission number generated by admission office of hospital.

Fluid management in control group patients was managed using routine cardiovascular and clinical monitoring. Fluid resuscitation of protocol group patients was guided for first 12 hours of ICU stay according to the protocol based on data obtained by esophageal Doppler. After 12 hours the esophageal probe was removed and following fluid management in both groups was guided in the same way as in control group.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17313691 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6f668c46-fac2-4460-82d1-d2d31d7319c5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17313691"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15700-0</funderId>
      <contactId>Contact53634_15700</contactId>
      <sponsorId>Sponsor52184</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53634_15700">
    <title>Dr</title>
    <forename>Ivan</forename>
    <surname>Chytra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Anesthesiology and Intensive Care Department
University Hospital
Alej svobody 80</address>
      <city>Plzen</city>
      <country>Czech Republic</country>
      <zip>30460</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chytra@fnplzen.cz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52184">
    <organisation>Charles University (Czech Republic)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine in Plzen
Husova 3</address>
      <city>Plzen</city>
      <country>Czech Republic</country>
      <zip>30605</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">office@lfp.cuni.cz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4491.8</gridId>
    <rorId>https://ror.org/024d6js02</rorId>
  </sponsor>
  <funder id="Funder15700-0">
    <name>The study was supported by the Czech Ministry of Education (project MSM0021620819) and by the Czech Ministry of Health (research grant IGA ND/7712-3).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-09-22T00:00:00.000Z">23549738</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multidisciplinary group intervention program to promote recovery after minor traffic injuries: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesised that in patients with combinations of risk factors for a protracted course, a multidisciplinary intervention with information about the injury, pain management and activity level, and support of healthy instead of illness behaviour, during the acute phase of rehabilitation might shorten the time to recovery.

The objective of this study was to assess the efficacy of such an intervention in patients with acute traffic related minor musculoskeletal injuries, rated to be at high risk for delayed recovery, based on the scores obtained in a newly developed prediction ruler (Prediction of Prolonged Self-perceived recovery after musculoskeletal injuries [PPS]).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was the patients&#146; self-perceived recovery at 12 months measured by the single question: "Do you feel recovered after the injury?" (yes/no).</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures were:
1. The Short Form health survey (SF-36)
2. The Short Musculoskeletal Function Assessment (SMFA)questionnaire
3. The Visual Analogue Scale (VAS) ratings regarding physical and mental distress and coping ability
4. Self-reported duration of sick leave</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local Ethics Committee, the Karolinska Institute, on the 11th June 2001 (reference number: 240/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23549738</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised Controlled Trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8d130a53-9f35-40e8-a264-1da4e9fa49f4">
	  <name>Ortopediska kliniken</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>118 83</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Potentially eligible patients had sustained traffic related minor musculoskeletal injuries (Injury Severity Scale [ISS] score less than nine) less than 24 hours before arrival to the emergency department. Consecutive patients were evaluated, but to be eligible for randomisation the patients had to have a high risk of prolonged recovery according to the PPS Questionnaire.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>135</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>135</totalTarget>
      <exclusion>1. A major musculoskeletal injury (ISS more than nine)
2. Aged over 18 years
3. Inability to read and understand spoken Swedish
4. Impaired cognitive function as judged by the investigators</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Traffic related minor musculoskeletal injuries</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Traffic related minor musculoskeletal injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Eligible patients were randomised to an intervention or a control group. Both groups received standard medical treatment according to the routines at the department.

The intervention (multidisciplinary treatment) group also received the following program: A team consisting of an orthopaedic surgeon (study doctor), an anaesthetist specialised in pain treatment, physiotherapist, study nurse and a psychologist carry out the intervention program consisting of group "lectures" where different topics are highlighted.

The aim of this "traffic injury school" is to, in a systematic and supportive manner, provide an information and discussion forum for topics that are relevant to all study patients regardless of the type of injury. The program consists of four short (about two hours) sessions once a week during a four-week period. The first lecture consists of an introduction to the program and a discussion about different coping mechanisms. The following three lectures deal with issues related to pain and pain treatment, the importance of physical training, how fractures and soft tissue injuries heal, and the interaction between mental and physical health.

All sessions are lead by the study doctor, anaesthetist, physiotherapist or psychologist and the study nurse participates in all sessions. After the introduction session the patients may participate in consecutive sessions or they can choose to come to later sessions as the groups are "open" and the "school" runs on a three week rolling schedule. After every session the patients rate their "control over the situation".  If the patient is in need of individual treatment (orthopaedic surgeon, physiotherapist, psychologist) an appointment can be arranged by the hospital.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17380190 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c905d14d-763d-4265-b32e-f9d709e8f564" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-03-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17380190"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15361-0</funderId>
      <funderId>Funder15361-1</funderId>
      <funderId>Funder15361-2</funderId>
      <funderId>Funder15361-3</funderId>
      <funderId>Funder15361-4</funderId>
      <contactId>Contact53290_15361</contactId>
      <sponsorId>Sponsor51837</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53290_15361">
    <title>Dr</title>
    <forename>Carin</forename>
    <surname>Ottosson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ortopediska kliniken
Södersjukhuset</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>118 83</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">carin.ottosson@sodersjukhuset.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51837">
    <organisation>Karolinska Institutet (Sweden)</organisation>
    <website>http://ki.se/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Clinical Science and Education
Södersjukhuset</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>118 83</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sari.ponzer@sodersjukhuset.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4714.6</gridId>
    <rorId>https://ror.org/056d84691</rorId>
  </sponsor>
  <funder id="Funder15361-0">
    <name>This study was supported by grants from:</name>
    <fundRef/>
  </funder>
  <funder id="Funder15361-1">
    <name>AFA Reseach foundation</name>
    <fundRef/>
  </funder>
  <funder id="Funder15361-2">
    <name>Cancer &amp; Traffic injury fund</name>
    <fundRef/>
  </funder>
  <funder id="Funder15361-3">
    <name>Försäkringsmedicinska Sällskapet.</name>
    <fundRef/>
  </funder>
  <funder id="Funder15361-4">
    <name>These grants have been directed solely to Department of Orthopaedics, Karolinska Institutet at Stockholm Söder Hospital. The funders had no involvement in the study.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-06-26T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-09-13T00:00:00.000Z">55819922</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of paroxetine treatment on glycaemic control and quality of life in mildly depressed type two diabetic subjects: a double-blind randomised placebo controlled six month trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesised that paroxetine will have a beneficial effect on quality of life and on glycaemic control in mildly depressed diabetics.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>10% decrease in HbA1c.</primaryOutcome>
      <secondaryOutcome>20% improvement in quality of life as defined by the RAND-36 health relate quality of life questionnaire.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Helsinki University Central Hospital ethics review committee has approved the study in 2001</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55819922</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="db3f01e1-a228-4fb9-9438-59f570820670">
	  <name>Psychiatric unit</name>
	  <address/>
	  <city>Vaasa</city>
	  <state/>
	  <country>Finland</country>
	  <zip>FIN-65130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Volunteers between 50 and 70 years of age 
2. Diagnosed type two diabetes
3. Hba1c more than 7.0% 
4. Mild symptoms of depression</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>38</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>38</totalTarget>
      <exclusion>1. Moderate to severe depression based on Diagnostic and Statistical Manual of mental disorders (DSM-IV) criteria
2. Severe diabetic complications 
3. Use of warfarin 
4. Glaucoma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type two diabetes mellitus and depression.</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Type two diabetes mellitus and depression.</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Paroxetin 20 mg per day or placebo for six months. Blood samples and clinical examination four times during the trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Paroxetine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17570858 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9573d531-e533-49d8-b476-470510afb816" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17570858"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15299-0</funderId>
      <contactId>Contact53204_15299</contactId>
      <sponsorId>Sponsor51750</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53204_15299">
    <title>Prof</title>
    <forename>Kristian</forename>
    <surname>Wahlbeck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Psychiatric unit
Vaasa Central Hospital</address>
      <city>Vaasa</city>
      <country>Finland</country>
      <zip>FIN-65130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kristian.wahlbeck@stakes.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51750">
    <organisation>GlaxoSmithKline (Finland)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Piispansilta 9 A
3 krs.
Espoo</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>02230</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">terese.m.pfister-peltola@sb.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.488284.a</gridId>
    <rorId>https://ror.org/01jxkq910</rorId>
  </sponsor>
  <funder id="Funder15299-0">
    <name>Funded by GlaxoSmithKline</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-03-05T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-07-26T00:00:00.000Z">48558333</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Low back pain education and quality of life: a randomized trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Low back education programme could improve quality of life in patients with low back pain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The principal outcome measure was quality of life. The mean increase in quality of life score above the baseline was used as the main outcome measure of the patients&#146; responses to the intervention.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Tehran University of Medical Sciences Ethics Committee in March 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48558333</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9a4d0fd0-5041-419a-9310-31a45bb21a6c">
	  <name>P.O. Box 13185-1488</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women age 18 years and over
2. Suffering from chronic back pain (persisting for 90 days or more)
3. Having a telephone number for regular contact with a responsible caregiver</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>102</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>102</totalTarget>
      <exclusion>1. Patients who had back surgery two years prior to the initial observation
2. If the complaint was restricted to the sacroiliac joint or the cervical or thoracic regions
3. Patients with congenital spine disease
4. Patients with a low back complaint that had persisted less than 90 days</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Low back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Low back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Back School Programme: the back school programme is a four-day, five-session, multidimensional and interdisciplinary educational regime designed to assess each patient&#146;s physical condition, personal characteristics, lifestyle and subsequent ability to cope.
Group 1: patients received medication and education with the back school programme.
Group 2: patients received the medication alone.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17328809 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fed435fe-0e7d-4d78-a284-f15c689e65fa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17328809"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15172-0</funderId>
      <contactId>Contact53038_15172</contactId>
      <sponsorId>Sponsor51582</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53038_15172">
    <title>Dr</title>
    <forename>Ali</forename>
    <surname>Montazeri</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 13185-1488</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0) 21 6409786</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ali@jdcord.jd.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51582">
    <organisation>Iranian Institute for Health Sciences Research (Iran)</organisation>
    <website>http://www.ihsr.ac.ir</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 13145-1756</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0) 21 66480804</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@ihsr.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414805.c</gridId>
    <rorId>https://ror.org/00yesn553</rorId>
  </sponsor>
  <funder id="Funder15172-0">
    <name>Iranian Institute for Health Sciences Research (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-06-27T00:00:00.000Z">06223266</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Acupuncture for chronic neck pain: a pilot for a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>That a randomised controlled trial is feasible and this design can be optimised in a pilot study</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Northwick Park neck pain questionnaire</primaryOutcome>
      <secondaryOutcome>1. Quality of life
2. EQ-5D
3. Medication use</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the York Local Research Ethics Committee in April 2005, reference number: 05/Q1108/14)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06223266</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A pilot for a randomised controlled trial (RCT)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="437beaa9-3887-4720-8fef-3f5a8a1aab7c">
	  <name>Department of Health Sciences</name>
	  <address/>
	  <city>York</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>YO10 5DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consulted general practitioner (GP) in the previous 12 months with neck pain, at least 18 years old, with neck pain duration of at least four weeks</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Known serious pathology (cancer), rheumatoid arthritis, ankylosing spondilitis, abnormal neurology in upper arms, main pain below the elbow, or in some other part of the body, surgery on the neck, haemophilia, currently receiving acupuncture, pending litigation related to their neck, unable to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic neck pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Acupuncture plus usual GP care versus usual GP care alone</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=%2017156464 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e3334bb8-fb47-405c-b395-4b20bde78666" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=%2017156464"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15153-0</funderId>
      <contactId>Contact53013_15153</contactId>
      <sponsorId>Sponsor51561</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53013_15153">
    <title>Dr</title>
    <forename>Hugh</forename>
    <surname>MacPherson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Health Sciences
University of York</address>
      <city>York</city>
      <country>United Kingdom</country>
      <zip>YO10 5DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1904 312394</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hm18@york.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51561">
    <organisation>University of York (UK)</organisation>
    <website>http://www.york.ac.uk/admin/ido</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Research and Industry Office
Heslington</address>
      <city>York</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>YO10 5DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1904 435102</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">smf3@york.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5685.e</gridId>
    <rorId>https://ror.org/04m01e293</rorId>
  </sponsor>
  <funder id="Funder15153-0">
    <name>University of York</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-31T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-05-15T00:00:00.000Z">31432640</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised double-blind, placebo-controlled trial of selenium supplementation in adult asthma</title>
      <scientificTitle/>
      <acronym>SELINA (SELenium IN Asthma)</acronym>
      <studyHypothesis>That a low intake of selenium, by increasing oxidative stress, promotes airway inflammation and worsens asthma symptoms, and that this effect can be ameliorated by supplementation with selenium, leading to a reduction in severity and even remission of asthma symptoms.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Asthma-related quality of life</primaryOutcome>
      <secondaryOutcome>1. Lung function
2. Asthma symptom scores
3. Peak flow
4. Bronchodilator usage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Greenwich Local Research Ethics Committee (LREC), main approval 21/11/01; amendments to protocol approved on 4/4/03, reference number: 82/NOV/01 and Guy's LREC main approval: 26/09/02; amendments to protocol approved on 19/11/02; 19/02/03; 15/05/03; reference number: 02/09/16</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31432640</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0534164211</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled trial (parallel design)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="29fd2a1e-e819-4298-a85c-9dbef6824827">
	  <name>Imperial College London</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W2 1PG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Asthma symptoms in last month
2. Prescribed inhaled steroids in last six months
3. Not taking selenium supplements</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200 (100 in each arm)</totalTarget>
      <exclusion>1. Inability to give informed consent
2. Inability to swallow tablets
3. Pregnancy or lactation or intention to become pregnant during the trial period
3. Renal or liver disease
4. Known yeast intolerance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Adult asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Selenium supplement 100 microgram (one tablet per day) versus placebo supplied by Pharma Nord, Denmark.  The product (SelenoPrecise ™) is a yeast preparation grown in a selenium-rich medium.  Placebo contains yeast only.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>SelenoPrecise</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17234657</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0f0531f4-e543-4509-923b-2efbd4f9c8fd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17234657"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15013-0</funderId>
      <contactId>Contact52833_15013</contactId>
      <sponsorId>Sponsor51382</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52833_15013">
    <title>Dr</title>
    <forename>Seif</forename>
    <surname>Shaheen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Imperial College London
Respiratory Epidemiology Group
National Heart and Lung Institute
St Mary's Campus
Norfolk Place</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W2 1PG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207 594 0948</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.shaheen@imperial.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51382">
    <organisation>Department of Health (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Chief Research Officer for Public Health
 Department of Health
Room 716 Wellington House
135-155 Waterloo Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE1 8UG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207 972 1347</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">william.maton-howarth@dh.gsi.gov.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.57981.32</gridId>
    <rorId>https://ror.org/03sbpja79</rorId>
  </sponsor>
  <funder id="Funder15013-0">
    <name>Department of Health Unit Grant, which core funds our Public Health Aspects of Asthma Research Programme (Social Medicine and Health Services Research Unit (ref: 121/7418, Unit Director and grant holder Prof P Burney).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-02-16T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-05-05T00:00:00.000Z">54261005</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment of uncomplicated falciparum malaria in Bobo-Dioulasso, 
Burkina Faso: comparison of amodiaquine sulfadoxine-pyrimethamine with Coartem</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The efficacy of amodiaquine sulfadoxine pyrimethamine and artemether lumefantrine for the treatment of uncomplicated falciparum malaria in Bobo-Dioulasso, Burkina Faso will be equivalent</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The risk of clinical and parasitological treatment failure after 28 days of follow-up. Pairwise comparisons between regimens will be made on based on a per protocol analysis.</primaryOutcome>
      <secondaryOutcome>1. Risk of clinical failure after 14 days of follow-up
2. Risk of rescue therapy after 28 days of follow-up
3. Risk of fever during the first 3 days of follow-up: presence or absence of objective fever (axillary temperature &gt;37.5 °C) or patient report of fever on days 1, 2, 3
4. Risk of parasitemia on follow-up days 2 and 3: proportion of positive versus negative thick blood smears on days 2 and 3
5. Change in mean hemoglobin from day 0 to 28 or day of repeat therapy
6. Proportion gametocytemic: presence versus absence of gametocytes on any follow-up thick blood smear; proportion gametocytemic on days 2, 3, 7, 14, 21, and 28
7. Risk of serious adverse events: proportion of patients experiencing any serious adverse event in each treatment group during the 28-day follow-up period, excluding treatment failures
8. Risk of adverse events of moderate or greater severity, at least possibly related to the study medications, excluding treatment failures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Review Board (IRB) Centre Muraz, University of California San Francisco Committee for Human Research, reference number: H2397-2758-01 and by the IRB Institute for Resource and Security Studies (IRSS), reference number: 019-2005/CE-CM</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54261005</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, single-blinded, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-22T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="623778d6-f070-4cc5-8395-670ac301c2d6">
	  <name>399 Avenue de la Liberte</name>
	  <address/>
	  <city>Bobo-Dioulasso</city>
	  <state/>
	  <country>Burkina Faso</country>
	  <zip>01</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age ≥6 months
2. Fever (≥37.5 or history of fever in the last 24 hours)
3. Provision of informed consent
4. P. falciparum mono infection
5. Parasite density &gt;2000 microliters and ≥200,000 microliters</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>521</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>521</totalTarget>
      <exclusion>1. Evidence of severe malaria
2. History of side effects to the investigational product
3. Pregnancy
4. Repeated vomiting of study medication on day 0
5. Hemoglobin &lt;5 g/Dl
6. Evidence of concomitant febrile illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-22T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will be randomized to receive treatment with amodiaquine sulfadoxine pyrimethamine or artemether lumefantrine. Subjects in amodiaquine group will receive placebo to ensure the same number of doses in the two groups. Repeated therapy will be quinine.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Amodiaquine sulfadoxine pyrimethamine and artemether lumefantrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17292769</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0e8e2491-8689-40ad-9fc5-14f219db05a3" outputType="abstract" artefactType="ExternalLink" dateCreated="2007-02-10T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17292769"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14932-0</funderId>
      <funderId>Funder14932-1</funderId>
      <contactId>Contact52729_14932</contactId>
      <sponsorId>Sponsor51267</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52729_14932">
    <title>Prof</title>
    <forename>Ouedraogo</forename>
    <surname>Jean Bosco</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>399 Avenue de la Liberte
P O Box 545</address>
      <city>Bobo-Dioulasso</city>
      <country>Burkina Faso</country>
      <zip>01</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 20981880</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbouedraogo.irss@fasonet.bf</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51267">
    <organisation>Institute of Research in Health Sciences  (Institut de Recherches en Sciences de la Sante [IRSS]) (Burkina Faso)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>399 Avenue de la Liberte
P O Box 545</address>
      <city>Bobo-Dioulasso</city>
      <country>Burkina Faso</country>
      <zip>01</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 20981880</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbouedraogo.irss@fasonet.bf</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.457337.1</gridId>
    <rorId>https://ror.org/05m88q091</rorId>
  </sponsor>
  <funder id="Funder14932-0">
    <name>Fogarty International Center (part of the National Institutes of Health (FIC-NIH), D43 TW01506-05 (subcontract TW/8420599)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14932-1">
    <name>National Budget of Institut de Recherches en Sciences de la Sante (IRSS) and International Atomic Energy Agency (IAEA) RAF 6/025</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-01-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-05-04T00:00:00.000Z">32569437</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of epidural lidocaine analgesia on labor and delivery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Epidural analgesia for labor does not affect the duration of the first or second stages of labor</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Epidural analgesia for labor does not prolong the first or second stages of labor</primaryOutcome>
      <secondaryOutcome>Epidural analgesia for labor does not affect neonatal apgar score</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of Kashan University of Medical sciences approved this research on 01/10/2002, reference number: 8112</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32569437</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>8112</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f25d7161-13ba-4b55-a631-33dac9911df2">
	  <name>5th Kilometers of Ravand Road</name>
	  <address/>
	  <city>Kashan</city>
	  <state/>
	  <country>Iran</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Nulliparity
2. Active labor
3. Cervical dilatation ≥4 cm
4. Single fetus with vertex presentation
5. American Society of Anesthesiologists (ASA) status 1
6. Request for analgesia</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>395</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>395</totalTarget>
      <exclusion>1. ASA status &gt;2
2. Age &lt;19 years old
3. Receiving analgesia prior to enrolment
4. Accidental dural puncture
5. Multiparity
6. Probable cephalopelvic disproportion on pelvic examination
7. Cervical dilatation to &gt;4 cm</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Labor pain</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Labor pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>197 women were randomized to receive epidural with bolus doses of 1% lidocaine, 198 women were randomized to receive single-dose intravenous meperidine 25 to 50 mg</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lidocaine, meperidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17176461 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="086a1700-6bfe-48e0-8af4-82c043a8814b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17176461"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15014-0</funderId>
      <contactId>Contact52834_15014</contactId>
      <sponsorId>Sponsor51383</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52834_15014">
    <title>Dr</title>
    <forename>Shahram</forename>
    <surname>Nafisi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>5th Kilometers of Ravand Road
Site Maskoni Pezeshkan
F1, No. 17</address>
      <city>Kashan</city>
      <country>Iran</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51383">
    <organisation>Kashan University of Medical Sciences (Iran)</organisation>
    <website>http://www.kaums.ac.ir</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>15 Khordad Square
Setad Markazi Daneshgah</address>
      <city>Kashan</city>
      <country>Iran</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.444768.d</gridId>
    <rorId>https://ror.org/03dc0dy65</rorId>
  </sponsor>
  <funder id="Funder15014-0">
    <name>Kashan University of Medical Sciences, Iran (8112)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-04-26T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-04-28T00:00:00.000Z">66473618</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Survivors at risk: a randomised controlled trial of primary prevention of complicated grief among first degree relatives of suicide victims</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A brief (four sessions) nurse-led family focused intervention, based on cognitive behavioral therapy and psycho-education, offered between three and six months following the suicide, prevents depressive and complicated grief symptoms at 13 months bereavement.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Depression (Center for Epidemiologic Studies Depression Scale [CESD])
2. Complicated grief (Inventory of Traumatic Grief  [ITG])
3. Traumatic Grief Evaluation of Response to Loss (TRGR2L)
4. Schedules for Clinical Assessment in Neuropsychiatry (SCAN)</primaryOutcome>
      <secondaryOutcome>1. Guilt
2. Relief
3. Satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (ref: METC 2002/137).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66473618</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>METC 2002/137</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1e53e4a3-c04c-4ffe-8ee8-695d7d2ebfab">
	  <name>University Medical Center Groningen (UMCG)</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families (first-degree relatives, in-laws and spouses) of suicide victims recruited in the three northern provinces of the Netherlands between 1 September 1999 and 1 January 2002.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>106</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>106</totalTarget>
      <exclusion>1. Severe mental illness
2. Imprisonment of the deceased
3. Lack of Dutch fluency</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Suicide bereavement, complicated grief</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Grief</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Brief, nurse-led family-focused four session intervention by trained psychiatric nurses, based on cognitive behavioural therapy and psycho-education versus care as usual (control).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17449505 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="49250fd5-6f7f-46c0-87ed-ffb688bdf7f4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17449505"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15030-0</funderId>
      <contactId>Contact52850_15030</contactId>
      <sponsorId>Sponsor51399</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52850_15030">
    <title>Dr</title>
    <forename>Marieke</forename>
    <surname>de Groot</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Groningen (UMCG)
Department of Social Psychiatry
P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3614701</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.h.de.groot@med.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51399">
    <organisation>University Medical Center Groningen (UMCG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15030-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-11-28T00:00:00.000Z">87720456</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A Simplified Goal-directed Protocol Improves Clinical Outcomes in Patients with Septic Shock: A Randomized Controlled Trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We sought to evaluate whether a goal-directed protocol, without measurement of central venous oxygen saturation (ScVO2), would improve survival in patients with septic shock.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>ICU and in-hospital mortality</primaryOutcome>
      <secondaryOutcome>Length of ICU stay, length of hospital stay, and duration of mechanical ventilation.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The institutional review board approved this study</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87720456</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A Randomized Controlled Trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ffa0f41d-e9ee-4f3e-a153-98485397c99e">
	  <name>199 Tun Hwa N. Road</name>
	  <address/>
	  <city>Taipei</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>105</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients admitted to intensive care unit (ICU) with diagnosis of septic shock were included in this study.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>224</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>224</totalTarget>
      <exclusion>Exclusion criteria included age less than 18 years, pregnancy, or the presence of an acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, cardiac dysrhythmias (as a primary diagnosis), active gastrointestinal hemorrhage, seizure, drug overdose, burn injury, trauma, a requirement for immediate surgery, uncured cancer, immunosuppression, do-not-resuscitate status, or patient or family refusal to participate.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Septic shock</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septicaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients with septic shock were randomly assigned to receive therapy with or without a written protocol utilizing central venous pressure, mean arterial pressure and urine output as therapeutic goals.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17117128 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5ee53fd6-3eb0-47d4-9c8f-c7ce77ddde07" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17117128"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14239-0</funderId>
      <contactId>Contact51962_14239</contactId>
      <sponsorId>Sponsor50392</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51962_14239">
    <title>Dr</title>
    <forename>Shu-Min</forename>
    <surname>Lin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>199 Tun Hwa N. Road
Department of Thoracic Medicine
Chang Gung Memorial Hospital</address>
      <city>Taipei</city>
      <country>Taiwan</country>
      <zip>105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 3 3272474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">smlin100@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50392">
    <organisation>Chang Gung Memorial Hospital (Taiwan)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Han-Pin Kuo
199 Tun Hwa N. Road
Department of Thoracic Medicine
Chang Gung Memorial Hospital</address>
      <city>Taipei</city>
      <country>Taiwan</country>
      <zip>105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 3 3272474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">q8828@ms11.hinet.net</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413801.f</gridId>
    <rorId>https://ror.org/02verss31</rorId>
  </sponsor>
  <funder id="Funder14239-0">
    <name>NSC-92-2314-B-182A-069, National Science Council, Taiwan, R.O.C</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-04-26T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">59427925</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial and economic evaluation of home-based medication and lifestyle review by community pharmacists for patients with heart failure</title>
      <scientificTitle/>
      <acronym>HeartMed</acronym>
      <studyHypothesis>That home-based medication and lifestyle review by community pharmacists can reduce hospital re-admissions in heart failure patients and improve quality of life.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total number of emergency hospital readmissions at six months</primaryOutcome>
      <secondaryOutcome>1. Total deaths at six months
2. Total heart failure hospital readmissions at six months
3. Self-assessed quality of life at six months using the EQ-5D and Minnesota living with heart failure questionnaire

Also: 
1. Admissions to residential or nursing homes at six months 
2. Self-assessed compliance at six months using the Medication Adherence Report scale
3. Self-assessed behaviour change at six months using the European heart failure self-care behaviour scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59427925</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PG/02/171</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5aa595de-d7ce-4322-90bd-0ae9d56028fb">
	  <name>School of Medicine</name>
	  <address/>
	  <city>Norwich</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NR4 7TJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult (over 18 years)
2. Discharged to home or warden controlled accommodation after an emergency admission in the last month with a primary clinical diagnosis of heart failure
3. Prescribed two or more drugs (oral or inhaled) taken on at least a daily basis 
4. Norfolk or Suffolk resident</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>306</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>306</totalTarget>
      <exclusion>1. Patients living in residential, nursing homes or long-stay hospitals  
2. All patients whose treatment includes planned surgery for ischaemic or valvular heart disease or awaiting heart transplantation 
3. All patients with concomitant terminal malignancy.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart Failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Home-based medication review and lifestyle advice by community pharmacists</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17452390 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e8ee37c0-7fa2-4205-817c-7f7c95647824" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17452390"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13530-0</funderId>
      <contactId>Contact51179_13530</contactId>
      <sponsorId>Sponsor49578</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51179_13530">
    <title>Dr</title>
    <forename>Richard</forename>
    <surname>Holland</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Medicine
Health Policy &amp; Practice
University of East Anglia</address>
      <city>Norwich</city>
      <country>United Kingdom</country>
      <zip>NR4 7TJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1603 593574</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.holland@uea.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49578">
    <organisation>University of East Anglia (UK)</organisation>
    <website>http://www.uea.ac.uk/business</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University of East Anglia</address>
      <city>Norwich</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>NR4 7TJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1603 591486</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.briggs@uea.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8273.e</gridId>
    <rorId>https://ror.org/026k5mg93</rorId>
  </sponsor>
  <funder id="Funder13530-0">
    <name>British Heart Foundation (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000274</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-08T00:00:00.000Z">63594484</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Thrombosis Prevention Trial</title>
      <scientificTitle/>
      <acronym>TPT</acronym>
      <studyHypothesis>That primary prevention treatment in men at high risk with low intensity oral anticoagulation with warfarin and/or 75 mg aspirin daily (i.e. factorial design) reduces coronary heart disease events by 30%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>All coronary heart disease events; fatal and non-fatal coronary events separately.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63594484</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1988-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d1983397-0c65-46c9-b00d-6370dd516794">
	  <name>Non-communicable Disease Epidemiology Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>In top 20% of risk score distribution based on smoking history, family history, systolic blood pressure, body mass index, blood cholesterol, factor VII activity, plasma fibrinogen. 5499 men aged 45-69 recruited in 108 practices in the Medical Research Council's General Practice Research Framework.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>5499</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>4500 (5499 actually recruited).</totalTarget>
      <exclusion>Already on antithrombotic treatment; high risk of bleeding; liver or renal disease; serious concomitant disease; at discretion of general practitioner</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1988-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Thrombosis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Thrombosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral anticoagulation with warfarin to International Normalised Ratio of 1.5 and/or 75 mg aspirin daily compared with double placebo treatment, i.e. four treatment groups:
1. Active warfarin and active aspirin
2. Active warfarin and placebo aspirin
3. Placebo warfarin and active aspirin
4. Placebo warfarin and placebo aspirin</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Warfarin and aspirin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1998 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9457092 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="345197f4-1164-4163-9b5d-3d8b67bf60b9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1998-01-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9457092"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13522-0</funderId>
      <contactId>Contact51184_13522</contactId>
      <sponsorId>Sponsor49583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51184_13522">
    <title>Prof</title>
    <forename>Tom</forename>
    <surname>Meade</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Non-communicable Disease Epidemiology Unit
London School of Hygiene and Tropical Medicine
Keppel Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7927 2182</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tom.meade@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49583">
    <organisation>Sponsor not defined - Record provided by the Medical Research Council (UK)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tom.meade@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13522-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-03-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">12335748</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical and economic implications of stepping down inhaled corticosteroids in patients with chronic stable asthma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The UK national guidelines for asthma management recommend a slow stepwise reduction of treatment in patients with chronic asthma which has been stable for a three to six month period. Inhaled steroids are highly effective in treating asthma, although, a plateau in the therapeutic response may exist for many asthmatic patients at doses below 1000 mcg daily. Concerns have been raised that some patients may be receiving inappropriately high doses of inhaled steroids. The aims of this study are to assess the clinical and economic implications of stepping down inhaled steroid treatment over a one year period on patients with chronic stable asthma receiving more than 1000 mcg inhaled steroid daily.

The primary objectives are:
1. To compare the number of exacerbations of asthma in the group in whom the dose of inhaled steroid is reduced by up to 50% with those in whom the dose is unaltered over a one year period;
2. To perform an economic evaluation of the two management plans. The benefit the proposed investigation may bring to the National Health Service (NHS) is the cost-effective use of inhaled steroid treatment in asthma.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Exacerbation rate</primaryOutcome>
      <secondaryOutcome>Inhaled steroid dose</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical approval obtained in 1998.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12335748</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4d4e9304-711c-4d8a-9525-a2faa11e6aa9">
	  <name>Department of Respiratory Medicine</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G12 0YN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult asthmatic patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Chronic Obstructive Pulmonary Disease (COPD) 
2. Low dose inhaled steroids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory tract diseases: Asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Step down inhaled steroid over one year</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Inhaled steroid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12763981 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="673bbe42-2ed1-4046-a773-8825c6a3aeaf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-05-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12763981"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5863-0</funderId>
      <contactId>Contact7289_5863</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7289_5863">
    <title>Prof</title>
    <forename>Neil</forename>
    <surname>Thomson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Respiratory Medicine
West Glasgow Hospitals University NHS Trust
1053 Gt. Western Road</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G12 0YN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 211 3241</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">n.c.thomson@clinmed.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5863-0">
    <name>NHS Asthma National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-03-13T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">78625210</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of oral prednisolone for viral-wheeze in pre-school children with stratification for serum level of Eosinophil Protein X (EPX)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This study will test the hypothesis that in preschool children with viral-wheeze, those with atopic pulmonary inflammation will respond to a short course of oral corticosteroids, whereas those with a structurally based vulnerability to wheeze will not.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Outcome will be assessed by parental scoring of respiratory symptoms using a diary card.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78625210</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>AM2/01/008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="569fe164-ad5d-40f8-a3b2-be09e871e66d">
	  <name>University of Leicester</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE2 7LX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children aged between 18 and 48 months of age presenting with viral-wheeze.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="18.0"/>
      <upperAgeLimit unit="Months" value="48.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>No exclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory tract diseases: Asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Children passing the inclusion criteria will be divided into two groups
a. Those with presenting serum EPX levels of greater than or equal to 25 ug/l
b. Those with EPX levels &lt;25 ug/l.
At the next episode of viral wheeze children in both groups will receive either placebo or a short course of oral prednisolone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=14602435</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d180a2c3-cb7a-40d6-8ea2-c4e012bb2422" outputType="abstract" artefactType="ExternalLink" dateCreated="2003-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=14602435"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5776-0</funderId>
      <contactId>Contact7221_5776</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7221_5776">
    <title>Dr</title>
    <forename>Jonathan</forename>
    <surname>Grigg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Leicester
Leicester Royal Infirmary
P.O. Box 65</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE2 7LX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)116 252 5840</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jg33@leicester.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5776-0">
    <name>NHS Asthma National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-04-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">45898562</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to assess the role of resistance assays in Human Immunodeficiency Virus (HIV) infection</title>
      <scientificTitle/>
      <acronym>ERA - Evaluation of Resistance Assays</acronym>
      <studyHypothesis>The main hypothesis is that providing genotypic resistance assays improves the treatment of HIV-infected individuals who are not highly treatment-experienced.  A subsidiary hypothesis is that phenotypic plus genotypic resistance testing is superior to genotypic resistance testing alone in HIV-infected individuals who are highly treatment-experienced.
The ERA trial was designed to assess the clinical utility of HIV resistance testing in patients who had failed therapy and whose most recent viral load was at least 2000 copies/ml.  Patients were randomised to one of two parts, depending on whether the clinician was able (Part A) or was not able (Part B) to select a regimen of 3 or more drugs that, with reasonable expectation, had potent anti-HIV activity and to which each drug contributed.  Patients in Part A were allocated to (a) no resistance test, or (b) a centralised genotypic assay (VIRCOGENTM).  All participants in Part B had the VIRCOGENTM assay and were randomised to have or not have in addition a centralised phenotypic assay (ANTIVIROGRAMTM).  Patients allocated to resistance testing had access to testing at any time during follow-up when clinically indicated, according to the original allocation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Plasma HIV-1 RNA at 12 months measured centrally at the Royal Free Hospital using the Roche ultra-sensitive assay (with a lower limit of detection of 50 copies/ml).</primaryOutcome>
      <secondaryOutcome>1. CD4 count at 12 months (all laboratories participate in the UK National Quality Assessment Scheme of SD4)
2. Antiretroviral treatment prescribed including the number of switches in therapy and drugs used (constructed from 3-monthly case record forms)
3. Adherence with antiretroviral treatment prescribed (assessed by a 3-monthly self-completed questionnaire)
4. Available drug options (as assessed by genotypic resistance) at 12 months
5. Progression to a new AIDS-defining events will be collected retrospectively on an annual basis after 12 months to enable long-term benefits to be assessed</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45898562</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RDC01658</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ba73cecd-1bbb-4b68-bfb7-f0f5999d60ce">
	  <name>MRC Clinical Trials</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NW1 2DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Confirmed HIV-positive 
2. Age 18 years or more 
3. Expected to live at least 12 months 
4. Able to give informed consent 
5. Currently receiving antiretroviral therapy 
6. Most recent HIV ribonucleic acid (RNA) &gt;2000 copies/ml 
7. Clinician and patients have decided to change therapy on the basis of virological failure 
8. Clinician considers that a resistance test may influence selection of new drug regimen, and clinician and patient are prepared to wait for the result (up to 1 month) before changing treatment</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>480</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>480</totalTarget>
      <exclusion>1. Naive to antiretroviral drugs or previous exposure to 1 or 2 nucleoside analogue reverse transcriptase inhibitors only
2. Part A only: a resistance test (genotypic or phenotypic) had previously been performed or patient would have had a local resistance test
3. Part B only: a phenotypic resistance test had previously been performed
4. Participation in certain trials of antiretroviral therapies, considered on a case-by-case basis
5. Was unlikely to comply with routine schedule of visits</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infection and infestations: HIV/Acquired Immunodeficiency Syndrome (AIDS)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV/Acquired Immunodeficiency Syndrome (AIDS)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Standard care
2. Access to a centralised genotypic assay with computer assisted interpretation
3. Access to a centralised phenotypic assay</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15793365 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="55bf3951-c4cd-4ed0-a3c9-6996fdbb27a4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15793365"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5894-0</funderId>
      <contactId>Contact7341_5894</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7341_5894">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Dunn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC Clinical Trials
222 Euston Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>NW1 2DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7670 4739</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.dunn@ctu.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5894-0">
    <name>NHS Executive London</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-04-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">65414827</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacological Treatment of Congenital Nystagmus</title>
      <scientificTitle/>
      <acronym>PTCN</acronym>
      <studyHypothesis>To investigate whether memantine and gabapentin improve nystagmus.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Visual acuity</primaryOutcome>
      <secondaryOutcome>Nystagmus amplitude</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Leicestershire Ethics Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65414827</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0123112717</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Placebo controlled randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bf2239ad-baaa-4866-8765-02f3ca22905f">
	  <name>University Hospitals of Leicester</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE1 4PW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Congenital nystagmus
2. Over 18 years of age</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Other neurological condition
2. Pregnancy or breastfeeding
3. Unable or unwilling to give consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nystagmus</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Nystagmus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of gabapentin, memantine or a placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Memantine and gabapentin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17279539 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2240d39c-8bc2-4513-a64c-760d9e99d09e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17279539"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5692-0</funderId>
      <funderId>Funder5692-1</funderId>
      <funderId>Funder5692-2</funderId>
      <contactId>Contact53073_5692</contactId>
      <sponsorId>Sponsor51620</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53073_5692">
    <title>Prof</title>
    <forename>Irene</forename>
    <surname>Gottlob</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospitals of Leicester
c/o Research and Development Office
Leicester General Hospital NHS Trust</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE1 4PW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51620">
    <organisation>University Hospitals Leicester (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Gwendolen House
Gwendolen Road</address>
      <city>Leicester</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>LE5 4QF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.269014.8</gridId>
    <rorId>https://ror.org/02fha3693</rorId>
  </sponsor>
  <funder id="Funder5692-0">
    <name>Nystagmus Network UK</name>
    <fundRef/>
  </funder>
  <funder id="Funder5692-1">
    <name>Ulverscroft Foundation</name>
    <fundRef>http://dx.doi.org/10.13039/501100001311</fundRef>
  </funder>
  <funder id="Funder5692-2">
    <name>University Hospitals of Leicester NHS Trust</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-03-06T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2003-01-03T00:00:00.000Z">55376150</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A pragmatic randomised controlled trial in primary care to determine the effectiveness of active physiotherapy treatment and enhanced pharmacy review for knee pain</title>
      <scientificTitle/>
      <acronym>TOPIK (Treatment Options for Pain In the Knee)</acronym>
      <studyHypothesis>The primary objective of this trial is to examine the clinical effectiveness, of two innovative interventions: enhanced pharmacy review and active physiotherapy, compared with a control group receiving an advice and information booklet reinforced with telephone support.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 6 months.</primaryOutcome>
      <secondaryOutcome>Anxiety and Depression (HADS); Confidence in managing pain, function, and other symptoms associated with arthritis (Arthritis Self-Efficacy Scale); Overall health status (EuroQoL).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55376150</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S0646</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6ad69526-1ccf-4ae8-9655-e4c9bb5ef5fe">
	  <name>Primary Care Sciences Research Centre</name>
	  <address/>
	  <city>Keele</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST5 5BG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female patients aged 55 years and above
2. Pain with or without stiffness in one or both knees 
3. Considered suitable for primary care management by GP
4. Able to read English
5. Available for telephone contact
6. Able and willing to consent to participation</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>325</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>325</totalTarget>
      <exclusion>1. Patients with potentially serious pathology (e.g. inflammatory arthritis, malignancy) on the basis of GP diagnosis or past medical history
2. Patients with severe disability: WOMAC Physical Function score ³ 40
3. Patients already on a surgical waiting list
4. Patients who have already had an exercise programme for their knee problem within the previous 3 months (normal recreational involvement in sport or exercise will not be an exclusion)
5. Patients who have received an intra-articular injection to the knee in the last 6 months
6. Patients who have a knee replacement
7. Patients unable or unwilling to receive the study interventions, or for whom the interventions are contraindicated
8. Patients with acute trauma
9. Knee pain due to malignancies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knee pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Knee pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Pharmacy review of medication
2. Active physiotherapy management
3. Advice leaflet</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17056608 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1e5b799d-88d9-45d6-8fec-719aa530381a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-11T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17056608"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1507-0</funderId>
      <contactId>Contact5055_1507</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5055_1507">
    <title>Dr</title>
    <forename>EM</forename>
    <surname>Hay</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Primary Care Sciences Research Centre
Keele University</address>
      <city>Keele</city>
      <country>United Kingdom</country>
      <zip>ST5 5BG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 583908</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.m.hay@cphc.keele.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1507-0">
    <name>Arthritis Research Campaign</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-05-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-09-12T00:00:00.000Z">70120585</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized controlled evaluation of the cost effectiveness of cognitive-behavioural guided self-care versus family therapy for adolescent bulimia nervosa in a catchment area-based population</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. In adolescents with bulimia nervosa or eating disorder not otherwise specified (EDNOS), family therapy (FT) will produce higher rates of abstinence from bingeing and vomiting, both post-treatment (6 months) and at follow-up (12 months) than individual cognitive behavioural guided self-care (CBT-GSC).
2. CBT-GSC will be less costly to implement than FT.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Abstinence rates from binging and vomiting over the previous month, assessed at 6 and 12 months on an observer-rated interview measure.</primaryOutcome>
      <secondaryOutcome>1. Abstinence rates from bingeing and vomiting over the previous month, assessed at 6 and 12 months on a questionnaire measure
2. Longitudinal assessment of bingeing and vomiting by interview
3. Other eating disorder symptoms
4. Cost of care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institute of Psychiatry Research and South London and Maudsley NHS Trust Research Ethics Committee. Date of approval 17/09/1999, reference number 163/99.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70120585</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1206/88</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-09-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="278cc660-66e9-49f6-9695-5924949643d8">
	  <name>Eating Disorder Research Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE5 8AF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 20 years or under, referred to one of the following study centres: Maudsley Eating Disorders Services, Surrey-Hampshire Borders Child and Adolescent Eating Disorders Services, Royal Free Eating Disorders Services, Phoenix Eating Disorders Service at St Ann's Hospital
2. Fulfil criteria for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) bulimia nervosa or eating disorders not otherwise specified</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>84</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>42 per group; 84 in total</totalTarget>
      <exclusion>1. A body mass index below the 10th centile for age and sex
2. Insufficient knowledge of English to understand the treatment manual
3. Learning disability, severe mental illness or alcohol/substance dependence</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-09-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bulimia nervosa</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Bulimia nervosa</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomly assigned to one of two groups: family therapy or guided-self care. 
1. Family Therapy: 15 conjoint family therapy sessions over 6 months
2. Guided-self Care: 10 individual weekly sessions, up to two additional sessions with a close other, then three follow-up sessions over the next 3 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17403972 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3fa8f619-3dad-4bf6-8b12-fea5844883b5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17403972"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1433-0</funderId>
      <contactId>Contact5202_1433</contactId>
      <sponsorId>Sponsor5112</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5202_1433">
    <title>Dr</title>
    <forename>Ulrike</forename>
    <surname>Schmidt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eating Disorder Research Unit
Division of Psychological Medicine
Institute of Psychiatry
De Crespigny Park</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7919 3180/7848 0181</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ulrike.schmidt@slam-tr.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5112">
    <organisation>The Health Foundation (UK)</organisation>
    <website>http://www.pppfoundation.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>90 Long Acre</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC2E 9RA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7257 8000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@health.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453604.0</gridId>
    <rorId>https://ror.org/02bzj4420</rorId>
  </sponsor>
  <funder id="Funder1433-0">
    <name>The Health Foundation</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>